



European Association of Urology

GUIDELINES ON TESTICULAR CANCER

**M.P. Laguna (Chairperson), O. Klepp, A. Horwich, F. Algaba,
C. Bokemeyer, G. Pizzocaro, G. Cohn-Cedemark, P. Albers**

TABLE OF CONTENTS	PAGE	
1	BACKGROUND	4
	1.1 Methods	4
2	PATHOLOGY AND NATURAL HISTORY	4
3	DIAGNOSIS	5
	3.1 Clinical examination	5
	3.2 Imaging of the Testis	5
	3.3 Serum Tumor Markers at diagnostic	5
	3.4 Inguinal exploration and orchiectomy	6
	3.5 Organ sparing surgery	6
	3.6 Pathological examination of the testis	6
	3.7 Diagnosis of Carcinoma in situ (Tin)	6
	3.8 Screening	7
4	STAGING	7
	4.1 Diagnostic tools	7
	4.2 Serum tumour markers. Postorchiectomy half-life kinetics	7
	4.3 Abdominal, mediastinal, supraclavicular nodes and viscera	7
	4.4 Staging and prognostic classifications	8
	4.5 Prognostic risk factors	10
5	IMPACT ON FERTILITY AND FERTILITY ASSOCIATED ISSUES	11
6	GUIDELINES ON DIAGNOSIS AND STAGING OF TESTICULAR CANCER	11
	6.1 References (Diagnosis and Staging testis tumor)	11
7	TREATMENT: STAGE I GERM CELL TUMOURS	18
	7.1 Stage I seminoma	18
	7.1.1 Prophylactic radiotherapy	18
	7.1.2 Surveillance	18
	7.1.3 Prophylactic chemotherapy	18
	7.1.4 Retroperitoneal Lymph Node Dissection (RPLND)	18
	7.2 Guidelines for the treatment of seminoma stage I	19
	7.3 NSGCT stage I	19
	7.3.1 Retroperitoneal Lymph Node Dissection (RPLND)	19
	7.3.2 Surveillance	19
	7.3.3 Primary chemotherapy	19
	7.3.4 Risk adapted treatment	20
	7.4 CS1S with (persistently) elevated serum tumour markers	20
	7.5 Guidelines on the treatment of NSGCT stage I	20
	7.6 References (Treatment Stage I Testis Tumor)	20
8	TREATMENT: METASTATIC GERM CELL TUMOURS	25
	8.1 Primary chemotherapy	25
	8.2 Restaging and further treatment	26
	8.2.1 Restaging	26
	8.2.2 Residual tumor resection	26
	8.2.3 Consolidation chemotherapy after secondary surgery	26
	8.3 Systemic Salvage treatment for relapse or refractory disease	26
	8.3.1 Seminoma	26
	8.3.2 Non Seminoma	26
	8.4 Salvage Surgery	27
	8.5 Treatment of brain metastases	27
	8.6 Guidelines for the treatment of metastatic germ cell tumours	27
	8.7 References (Treatment of Metastatic disease)	27

9	FOLLOW-UP AFTER CURATIVE THERAPY	37
9.1	General considerations	37
9.2	References (General considerations)	38
9.3	Follow-up stage I Non-seminoma	38
9.3.1	Follow-up after surveillance	38
9.3.2	Follow-up after nerve-sparing RLND	38
9.3.3	Follow-up after adjuvant chemotherapy	39
9.4	References (Follow-up Stage I Nonseminoma)	39
9.5	Follow-up: stage I Seminoma	41
9.5.1	Follow-up after radiotherapy	41
9.5.2	Follow-up after surveillance	41
9.5.3	Follow-up after adjuvant chemotherapy	42
9.6	References (Follow-up stage I Seminoma)	42
9.7	Follow-up stage II and advanced (metastatic) disease	44
9.7.1	Clinical and pathological stage II NSGCT	44
9.7.1.1	Relapse after primary RPLND	44
9.7.1.2	Relapse after primary chemotherapy	45
9.7.2	Clinical stage II Seminoma	46
9.7.3	Clinical stage IIc and III Seminoma and Non-Seminoma	46
9.8	References (Follow-up advanced disease)	47
10	ABBREVIATIONS	50

1 BACKGROUND

Testicular cancer represents between 1% and 1.5% of male neoplasms and 5% of urological tumours in general, with 3-6 new cases/occurring per 100,000 males/per year in Western society (1,2). An increase in the incidence of testicular cancer was detected during the 1970's and 1980's, particularly in Northern European countries and a recent review shows a clear trend toward an increased Testicular Cancer incidence in the last 30 years in the majority of the industrialized countries in North America, Europe and Oceania but surprising differences in incidence rates are seen between neighboring countries (3). Data from the Surveillance Epidemiology and End Results Program during the years 1973 to 1998 show a continuing increased risk among white men in USA only for seminoma (4).

Only 1-2% of cases are bilateral. The histological type varies, although there is a clear predominance (90-95%) of germ cell tumours (1). Peak incidence is in the third decade of life for non-seminoma and in the fourth decade for pure seminoma. Familial clustering has been observed, particularly among siblings (5).

Genetic changes have been described in patients with testicular cancer. A specific genetic marker (an isochromosome of the short arm of chromosome 12, i(12p), has been described in all histological types of germ cell tumours (5). Intratubular germ cell neoplasia (Tin) shows the same chromosomal changes, and recently alterations in the p53 locus have been found in 66% of cases of testicular Tin (6).

Epidemiological risk factors for the development of testicular tumors are: a history of chryptorchidism or undescended testis, Klinefelter's syndrome, familial history of testicular tumors among first grade relatives (father /brothers), the presence of a contralateral tumor or Tin and infertility (7-12). Tallness is associated with risk of germ cell cancer in a recent study (13) although further confirmation is needed.

Currently, testicular tumours show excellent cure rates. The main factors contributing to this are: careful staging at the time of diagnosis; adequate early treatment based on chemotherapeutic combinations, with or without radiotherapy and surgery; and very strict follow-up and salvage therapies. In the last decade, a decrease in the mean time delay to diagnosis and to treatment has been observed (14). In the treatment of Testicular Cancer the choice of the Center where this treatment is going to be administered is of capital importance. Although early stages can be successfully treated in a non reference Center, the relapse rate is higher, suggesting that the high survival rate is due to the chemo- and radiosensitivity of the early stages rather than the compliance achieved in the non reference Center (15). In poor prognosis non seminomatous germ cell tumors overall survival is significantly different (worse) depending on the number of patients treated at the Institution (< 5) (16).

1.1 Methods

The present Guidelines represent an implementation of the previously published texts; the latest guideline text was published in 2002. A multidisciplinary team of urologists, medical oncologists, radiotherapists and a pathologist were involved in producing the present text which is based on a non-structured review of the literature through 2003. Also data from Meta-analysis studies, Cochrane evidence and the recommendations of the European Germ Cell Cancer Collaborative Group, as well as other available guidelines have been included (17-23). Whenever possible, references have been labelled according to the principles of Evidence Based Medicine (24). The nature of the recommendations in the present guidelines is labelled according to grade of evidence (24).

2 PATHOLOGY AND NATURAL HISTORY

In seminoma Stage I the tumor size and the invasion of the rete testis are independent predictors of relapse. No molecular marker (CD30 and citokeratins) is useful.

In the non-seminoma and non- teratoma gem cell tumors the vascular invasion and stage are the most important morphological predictors. The behaviour of teratoma in the two different age groups is different; in prepuberal individuals testis teratoma is benign while in the postpuberal group metastases can appear in 27-33% of the cases.

The recommended pathological classification (modified from the World Health Organization) is shown below (25).

1. Germ cell tumours
 - Intratubular germ cell neoplasia
 - Seminoma (including cases with syncytiotrophoblastic cells)
 - Spermatocytic seminoma (mention if there is sarcomatous component)
 - Embryonal carcinoma

- Yolk sac tumour:
 - Reticular, solid and polyvesicular patterns
 - Parietal, intestinal, hepatoid and mesenchymal differentiation
 - Choriocarcinoma
 - Teratoma (mature, immature, with malignant component)
 - Tumours with more than one histological type (specify % of individual components)
2. Sex cord stromal tumours
 - Leydig cell tumour
 - Sertoli cell tumour (typical, sclerosing, large cell calcifying)
 - Granulosa (adult and juvenile)
 - Mixed
 - Unclassified
 3. Mixed germ cell/sex cord stromal tumours

3 DIAGNOSIS

3.1 Clinical Examination

Testicular cancer generally affects young men in the third or fourth decade of life. It normally appears as a painless, unilateral mass in the scrotum or the casual finding of an intrascrotal mass (26). In approximately 20% of cases the first symptom is scrotal pain and up to 27% of patients with testicular cancer have local pain (1). Occasionally, trauma to the scrotum may reveal the presence of a testicular mass. Gynaecomastia appears in 7% of cases and is more common in non-seminomatous tumours. Back and flank pain are present in about 11% of cases (14). Reduction in testis size can precede a testicular tumour (27).

In about 10% of cases, a testicular tumour can mimic an orchioepididymitis, with consequent delay of the correct diagnosis (1,2). Ultrasound must be performed in any doubtful case. Physical examination reveals the features of the mass and must always be carried out in conjunction with a general examination in order to find possible (supraclavicular) distant metastases, a palpable abdominal mass or gynaecomastia. A correct diagnosis must be established in all patients with an intrascrotum mass (28).

3.2 Imaging of the testis

Currently, diagnostic ultrasound serves to confirm the presence of a testicular mass and to explore the contralateral testis. Its sensitivity in detecting a testicular tumour is almost 100%, and it has an important role in determining whether a mass is intra- or extratesticular (29). Ultrasound is an inexpensive test, but it is unnecessary when the presence of a testicular tumour is clinically evident (30). Ultrasound of the testis has to be performed in young men without a palpable testicular mass who have retroperitoneal or visceral masses or elevated serum beta-hCG or AFP (31-34). The main uses of ultrasound are as a screening test of the contralateral testis in the follow-up of patients at risk (35).

Magnetic Resonance Imaging (MRI) offers higher sensitivity and specificity than ultrasound for diagnosing tumours (36-38) and may be able to differentiate seminomatous from non-seminomatous tumours. MRI of the scrotum offers a sensitivity of 100% and a specificity of 95-100% (39), but its high cost does not justify its use for diagnosis.

3.3 Serum tumor markers at diagnostic

Serum tumour markers are prognostic factors and contribute to diagnosis and staging (40). The following markers should be determined:

- AFP (produced by yolk sac cells)
- Beta-hCG (b-hCG) (expression of trophoblasts)
- LDH (marker of tissue destruction)

Globally, there is an increase in these markers in 51% of cases of testicular cancer (14,26). Alpha-Fetoprotein (AFP) increases in 50-70% of patients with non-seminomatous germ cell tumour (NSGCT) and a rise in beta-human chorionic gonadotrophin (hCG) is seen in 40-60% of patients with NSGCT. About 90% of non-seminomatous tumours present with a rise in one or two of the markers. Up to 30% of seminomas can present or develop an elevated beta-hCG level during the course of the disease (41,42). Lactate Dehydrogenase (LDH) is a less specific marker, and its concentration is proportional to tumour volume. Its level may be elevated in 80% of patients with advanced testicular cancer (41). It should be noted that negative markers levels do not

exclude the diagnosis of a germ cell tumour. Other markers studied include neuro-specific enolase (NSE) and placental alkaline phosphatase (PLAP). NSE and/or PLAP may be of limited value in monitoring patients with pure seminoma. Cytogenetic and molecular markers are available in specific centres, but at present only contribute to research studies.

Measurement of serum AFP, beta-hCG and LDH is mandatory. NSE and PLAP are optional.

3.4 Inguinal exploration and orchiectomy

Every patient with a suspected testicular mass must undergo inguinal exploration with exteriorization of the testis within its tunics, and immediate orchiectomy with division of the spermatic cord at the internal inguinal ring has to be performed if a tumour is found. The spermatic cord is isolated at the external ring and clamped with a soft vascular clamp. The testis is then exteriorized with its tunics. The surgical field is protected with surgical sponges, the tunica vaginalis is opened, and the testis is carefully inspected and palpated. If the diagnosis is not clear, a testicular biopsy is taken for frozen section histological examination. Once the diagnosis of testicular tumour has been established, the testis is enveloped into the sponges which protected the surgical field, gloves are changed, the inguinal channel is opened and the spermatic cord is divided at the level of the internal ring. The specimen is sent for definitive histology.

In case of disseminated disease and life-threatening metastases, up-front chemotherapy can be started and orchiectomy delayed until clinical stabilisation.

3.5 Organ sparing surgery

Although organ sparing surgery is not indicated it can be attempted in special cases with all the necessary precautions.

In synchronous bilateral testicular tumors, metachronous contralateral tumors or in a tumor in a solitary testis with normal preoperative testosterone levels, organ preserving surgery can be performed when the tumor measures less than 2 cm and surgical rules are respected. In those cases, the rate of associated Tin is high (up to 82%) and can be treated with radiotherapy (43).

The option has to be carefully discussed with the patient and surgery performed in a center with experience (44,45).

3.6 Pathological examination of the testis

After surgical ablation of the testis, pathological assessment is mandatory and determination of serum tumour markers is advisable.

Mandatory pathological requirements

- Macroscopic features: side, testis size, tumoural maximum size and macroscopic features of epididymis, spermatic cord and tunica vaginalis.
- Sampling: 1 cm² section for every cm of maximal tumoural diameter, including normal macroscopic parenchyma (if present), albuginea and epididymis selection of suspected areas. At least one proximal and one distal section of spermatic cord plus any suspected area.
- Microscopic features and diagnosis: histological type (specify individual components and estimate amount as percentage).
Presence or absence of peri-tumoral venous and/or lymphatic invasion.
Presence or absence of albuginea, tunica vaginalis, epididymis or spermatic cord invasion.
Presence or absence of intratubular germinal neoplasia (Tin) in non-tumoral parenchyma.
- Category pT category according to TNM 2002.
- Immunohistochemical studies: in seminoma and mixed germ cell tumour, AFP and beta-hCG.

Advisable immunohistochemical markers

- In seminoma: cytokeratins (CAM 5.2), PLAP
- In intratubular germ cell neoplasia: PLAP
- Other advisable markers: Chromogranine A (Cg A), Ki 1, and NSE

3.7 Diagnosis of carcinoma in situ (Tin)

Contralateral biopsy has been advocated to rule out the presence of Tin (46). Although this is routine policy in some countries, the low incidence of Tin and contralateral asynchronous testicular tumours, up to 5% and approximately 2.5% respectively, (27,47-50), the morbidity of Tin treatment and the fact that most of these asynchronous tumours are at a low stage at presentation make it controversial to recommend a systematic contralateral biopsy (50,51). It is still difficult to reach a consensus whether the existence of contralateral Tin has to be identified in all cases. However biopsy of the contralateral testis should be offered to high-risk patients for contralateral Tin with a testicular volume less than 12 ml, a history of chryptorchidism and younger than 30 years of age (48,53).

Once Tin is diagnosed, local Radiotherapy (up to 18 Gy) is the treatment of choice. Because this may produce infertility, the patient must be carefully counselled before treatment commences (48).

3.8 Screening

Although there are no surveys proving the advantages of screening programmes, it has been demonstrated that stage and prognosis are directly related to early diagnosis. In the presence of clinical risk factors, some self-physical examination by the affected individual is advisable.

4 STAGING

Staging represents the cornerstone on which testicular cancer treatment is based. After diagnostic and determination of the histological type staging is mandatory. To determine the presence of metastatic or occult disease half life kinetics of serum tumors markers has to be assessed, the nodal pathway has to be screened and the presence of visceral metastases ruled out.

Consequently, it is mandatory to assess:

- Post-orchietomy half life kinetics of serum tumour markers
- Status of abdominal and supraclavicular nodes, and the liver
- Presence or absence of mediastinal nodal involvement and lung metastases
- Status of brain and bone if any suspicious symptoms are present

4.1 Diagnostic tools

The currently available test include: serial blood sampling, chest X-ray, abdominal and thoracic CT scan, abdomen ultrasound, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) scan and other specific examinations depending on clinical suspicion.

4.2 Serum tumor markers. Postorchietomy half-life kinetics

The mean serum half-life of AFP is 5-7 days and that of beta-hCG approximately 1 day (41). Tumor markers have to be reevaluated after orchietomy to determine half life kinetics. The persistence of elevated serum tumor markers 3 weeks after orchietomy indicates the presence of metastatic disease (macro or microscopically) while normalization of marker levels after treatment does not necessarily mean the absence of a tumour. During chemotherapy the markers decline or persistence has a prognostic value.

4.3 Abdominal, mediastinal, supraclavicular nodes and viscera

Abdominal and mediastinal nodes are best assessed by means of CT scan.

The supraclavicular nodes are best assessed by physical examination.

CT scanning has clear advantages over lymphography in assessing retroperitoneal metastatic disease. It offers a sensitivity of 70-80% in the determination of the state of retroperitoneal nodes. Its accuracy depends on the size of the nodes; sensitivity and negative predictive value increase using a 3-mm threshold to define metastatic nodes in the landing zones (54). Those figures decrease slightly in stages I and II (55,56), with a rate of understaging of 25-30% (57). New generations of CT scans do not seem to improve the sensitivity.

An abdominal CT scan is mandatory but can be considered optional in very slim young men and children, in whom ultrasound must be performed due to lack of retroperitoneal fat.

MRI produces similar results to CT scanning in the detection of retroperitoneal nodal enlargement (58).

Again, the main objections to its routine use are high cost and limited access. Nevertheless, MRI can be very helpful when abdominal CT or ultrasound are inconclusive (58), when CT scan is contraindicated because of allergy to contrast media or when the physician or the patient are concerned about radiation dose. MRI is an optional test and there are currently no indications for its systematic use in the staging of testicular cancer.

Chest X-ray is the routine thorax examination. An antero-posterior and lateral chest X-ray could be considered the only thoracic examination in seminoma when retroperitoneal and pelvic CT scans are negative (59). A chest CT scan is the most sensitive way to evaluate the thorax and mediastinal nodes. This exploration has to be recommended in patients with NSGCT because up to 10% of cases can present with small subpleural nodes that are not visible radiologically (1). The CT scan has high sensitivity but low specificity (58). A chest CT is mandatory in all patients with NSGCT and in those with seminoma and positive abdominal CT scan (59).

There is not yet enough evidence to support the use of the fluorodeoxyglucose-positron-emission tomography (FDG-PET) scan in early testis tumor stages, it can nevertheless be recommended in the follow-up of seminoma post-chemotherapy residual masses bigger than 3 cm in order to decide Watchful Waiting (WW) or active treatment therapy (60-63).

Other examinations, such as brain or spinal CT, bone scan or liver ultrasound, should be performed if there is suspicion of metastases to these organs. CT scan or MRI of the skull are advisable in patients with NSGCT and widespread lung metastases. Table I shows the recommended test at staging

Table 1: Recommended tests for staging at diagnosis

Test	Recommendation grade B	Recommendation grade C
Serum tumor markers	Alpha – fetoprotein β – hCG LDH	
Abdomen CT scan	All patients	Slim adolescent
Chest X-ray	Seminoma (a)	
Chest CT scan	NSGCT	
Testis ultrasound	Clinical suspicion and normal scrotum at palpation	
MRI	When abdominal CT is inconclusive	All cases
PET scan (b)	Follow-up residual masses in seminoma	Follow-up residual masses in seminoma
Other	If clinical suspicion	

(a) If negative abdominal computed tomography (CT) scan.

(b) There is currently no indication for PET scan at diagnosis.

4.4 Staging and prognostic classifications

There are multiple staging systems, generally based on the quantity of tumoural volume at diagnosis and take into account known risk factors.

Among them the tumour, node, visceral metastasis (TNM) system, the Peckham classification (Royal Marsden Hospital), the Walter Reed Hospital classification and staging systems from the European Organization for Research and Treatment of Cancer (EORTC), Memorial Sloan Kettering (MMSK) and Indiana University Hospital. It appears that each group working in the field of testicular cancer has its own staging system. The most commonly systems used in Europe are the TNM and the Peckham classification.

The staging system recommended in these guidelines is the 2002 TNM of the UICC (International Union Against Cancer) (Table 2) (64).

This includes: determination of the anatomical extent of disease; assessment of serum tumour markers: including nadir values of beta-human chorionic gonadotrophin (beta-hCG), alpha-fetoprotein (AFP) and lactate dehydrogenase (LDH) after orchiectomy (S category); clear definition of regional nodes; and some N category modifications related to the node size.

Table 2: TNM classification for testicular cancer (UICC, 2002 Sixth Edition)

pT Primary Tumour¹

pTX	Primary tumour cannot be assessed (see 1, T-Primary tumour)
pT0	No evidence of primary tumour (e.g. histologic scar in testis)
pTis	Intratubular germ cell neoplasia (carcinoma in situ)
pT1	Tumour limited to testis and epididymis without vascular/lymphatic invasion: tumour may invade tunica albuginea but not tunica vaginalis
pT2	Tumour limited to testis and epididymis with vascular/lymphatic invasion, or tumour extending through tunica albuginea with involvement of tunica vaginalis
pT3	Tumour invades spermatic cord with or without vascular/lymphatic invasion
pT4	Tumour invades scrotum with or without vascular/lymphatic invasion

N Regional Lymph Nodes clinical

NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis with a lymph node mass 2 cm or less in greatest dimension or multiple lymph nodes, none more than 2 cm in greatest dimension
N2	Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension, or multiple lymph nodes, any one mass more than 2 cm but not more than 5 cm in greatest dimension
N3	Metastasis with a lymph node mass more than 5 cm in greatest dimension

pN Pathological

pNX	Regional lymph nodes cannot be assessed
pN0	No regional lymph node metastasis
pN1	Metastasis with a lymph node mass 2 cm or less in greatest dimension and 5 or fewer positive nodes, none more than 2 cm in greatest dimension
pN2	Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or more than 5 nodes positive, none more than 5 cm; or evidence of extranodal extension of tumour
pN3	Metastasis with a lymph node mass more than 5 cm in greatest dimension

M Distant Metastasis

MX	Distant metastasis cannot be assessed
M0	No distant metastasis
M1	Distant metastasis
M1a	Non-regional lymph node(s) or lung
M1b	Other sites

S Serum Tumour Markers

Sx	Serum marker studies not available or not performed
S0	Serum marker study levels within normal limits

LDH (U/L)		hCG (mIU/ml)		AFP (ng/ml)
S1 < 1.5 x N	and	< 5,000	and	< 1,000
S2 1.5– 10xN	or	5,000–50,000	or	1,000–10,000
S3 > 10 x N	or	>50,000	or	>10,000

N Indicates the upper limit of normal for the LDH assay.

¹ Except for PTis and pT4, where radical orchiectomy is not always necessary for classification purposes, the extent of the primary tumour is classified after radical orchiectomy; see pT. In other circumstances, TX is used if no radical orchiectomy has been performed.

According to the 2002 TNM classification, stage I testicular cancer includes the following substages:

Stage IA	pT1	N0	M0	S0
Stage IB	pT2, pT3 or pT4	N0	M0	S0
Stage IS	Any pT/TX	N0	M0	S1-3

Stage IA patients have primary tumours limited to the testis and epididymis, with no evidence of microscopic vascular or lymphatic invasion by tumour cells on microscopy, no sign of metastases on clinical examination or imaging, and post-orchiectomy serum tumour marker levels within normal limits. Stage IB patients have a more locally invasive primary tumour, but no sign of metastatic disease. Stage IS patients have persistently elevated (and usually increasing) serum tumour marker levels after orchiectomy, which is evidence of subclinical metastatic disease (or possibly a second germ cell tumour in the remaining testis). If serum tumour marker levels are declining according to the expected half-time decay after orchiectomy, the patient is usually followed up until normalization.

In large, population-based patient series, 75–80% of seminoma patients and about 55% of patients with non-seminomatous germ cell testicular cancer (NSGCT) have stage I disease at diagnosis (65,66). True stage IS (persistently elevated or increasing serum marker levels after orchiectomy) is found in about 5% of non-seminoma patients. If a staging retroperitoneal lymph nodes dissection (RPLND) is performed in stage IS patients, nearly all patients have pathological stage II disease (pN+) (1,2,5,65).

In 1997 the International Germ Cell Cancer Collaborative Group (IGCCCG), defined a prognostic-factor based staging system for metastatic testis tumor based on identification of some clinical independent adverse factors. This staging system has been incorporated into the TNM Classification and uses histology, location of the primary tumor, location of metastases and markers levels in serum as prognostic factors to categorize patients into “good”, “intermediate” or “poor” prognosis (67) (Table 3).

**Table 3: Prognostic-based staging system for metastatic germ cell cancer
(International Germ Cell Cancer Collaborative Group)**

Good prognosis group	
<i>Non-seminoma</i>	
56% of cases	<i>All of the following criteria:</i>
5-year PFS 89%	
5-year survival 92%	
	<ul style="list-style-type: none"> • Testis/retroperitoneal primary • No non-pulmonary visceral metastases • AFP < 1,000 ng/ml • β-hCG < 5,000 mIU/L (1,000 ng/ml) • LDH < 1.5 x ULN
<i>Seminoma</i>	
90% of cases	<i>All of the following criteria:</i>
5-year PFS 82%	
5-year survival 86%	
	<ul style="list-style-type: none"> • Any primary site • No non-pulmonary visceral metastases • Normal AFP • Any β-hCG • Any LDH
Intermediate prognosis group	
<i>Non-seminoma</i>	
28% of cases	<i>All of the following criteria:</i>
5 years PFS 75%	
5-year survival 80%	
	<ul style="list-style-type: none"> • Testis/retroperitoneal primary • No non-pulmonary visceral metastases • AFP > 1,000 and < 10,000 ng/ml or • β-hCG > 5000 and < 50,000 mIU/l or
	<ul style="list-style-type: none"> • LDH > 1.5 and < 10 x ULN
<i>Seminoma</i>	
10% of cases	<i>Any of the following criteria:</i>
5-year PFS 67%	
5-year survival 72%	
	<ul style="list-style-type: none"> • Any primary site • Non-pulmonary visceral metastases • Normal AFP • Any β-hCG • Any LDH
Poor prognosis group	
<i>Non-seminoma</i>	
16% of cases	<i>Any of the following criteria:</i>
5-year PFS 41%	
5-year survival 48%	
	<ul style="list-style-type: none"> • Mediastinal primary • Non-pulmonary visceral metastases • AFP > 10,000 ng/ml or • β-hCG > 50,000 mIU/L (10,000 ng/ml) or
	<ul style="list-style-type: none"> • LDH > 10 x ULN
<i>Seminoma</i>	
No patients classified as poor prognosis	

PFS = progression-free survival;

AFP = alpha-fetoprotein;

β -hCG = beta-human chorionic gonadotrophin;

LDH = lactate dehydrogenase

4.5 Prognostic risk factors

A series of pathological risk factors have been identified in all staging systems, which consequently have a bearing on the prognosis. (11-16). For clinical stage I, the most important risk factors are the histological type (seminomatous or non-seminomatous) and the presence of peri-tumoural vascular and lymphatic invasion for Non-Seminoma Stage I (68,69).

For seminoma Stage I on multivariate analysis tumor size (< or = 4 cm) and invasion of the rete testis remained the most important predictors for relapse (1, 7).

The significant prognostic pathological risk factors for stage I and clinical risk factors for metastatic disease are listed in table 4.

Table 4: Prognostic risk factors for testicular cancer

Pathological (for stage I)

- Histopathological type
 - For seminoma
 - Tumor size (= or > 4 cm)
 - Invasion of the rete testis
 - For Non-seminoma
 - Vascular/lymphatic in or peri-tumoral invasion
-

Clinical (for metastatic disease)

- Primary location
 - Elevation of tumour marker levels
 - Presence of non-pulmonary visceral metastasis^a
-

^a Only clinical predictive factor for metastatic disease in seminoma.

5 IMPACT ON FERTILITY AND FERTILITY ASSOCIATED ISSUES

Sperm abnormalities are not infrequent in patients with Testis Tumors. Furthermore chemotherapy treatment can also impair fertility. In patients in the reproductive age, pre-treatment fertility assessment (Testosterone, Luteinizing Hormone (LH) and FSH levels) and sperm analysis should be performed and cryopreservation offered if desired.

Cryopreservation should be performed before or after orchiectomy, but in any case prior to chemotherapy treatment (70-77).

In case of bilateral orchiectomy or low testosterone levels after treatment of Tin, long-life testosterone supplementation is recommended (78). For more detailed information the reader is referred to the EAU Male Infertility Guidelines.

6 GUIDELINES ON DIAGNOSIS AND STAGING OF TESTICULAR CANCER

1. Physical examination may be sufficient for the diagnosis of testicular cancer (GRADE B recommendation).
2. Testicular ultrasound is mandatory when a tumour is clinically suspected but the examination of the scrotum is normal, or if there is any doubt about the clinical findings in the scrotum (GRADE B recommendation).
3. Orchiectomy and pathological examination of the testis is necessary to confirm the diagnosis and define the local extension (pT category) (GRADE B recommendation). Nevertheless in an emergency clinical situation chemotherapy can be started before orchiectomy.
4. Serum determination of tumour markers (AFP, beta-hCG, LDH) must be performed before and after orchiectomy for staging and prognostic reasons (GRADE B recommendation).
5. Retroperitoneal, mediastinal and supraclavicular nodes and visceral state have to be assessed in testicular cancer. In seminoma, a chest CT scan is not necessary if abdominal nodes are negative (GRADE B recommendation).

6.1 REFERENCES (Diagnosis and Staging of Testis Tumor)

1. **Richie JP.**
Neoplasms of the testis. In: Campbell's Urology. 7th ed. Walsh PC et al. (eds). WB Saunders Co.: Philadelphia, 1997, 2411-2452.

2. **Schottenfeld D, Warshauer ME, Sherlock S, Zauber AG, Leder M, Payne R.**
The epidemiology of testicular cancer in young adults. Am J Epidemiol 1980;112:232-246. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6106385&dopt=Abstract
3. **Huyghe E, Matsuda T, Thonneau P.**
Increasing incidence of testicular cancer worldwide: a review. J Urol, 2003;170(1):5-11. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12796635&dopt=Abstract
4. **McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE.**
Trends in the incidence of testicular germ cell tumors in the United States. Cancer, 2003;97(1): 63-70. EBM III-Ilb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12491506&dopt=Abstract
5. **Bosl GJ, Motzer RJ.**
Testicular germ-cell cancer. N Engl J Med 1997;337:242-253.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9227931&dopt=Abstract
6. **Kuczyk MA, Serth J, Bokemeyer C, Jonassen J, Machtens S, Werner M, Jonas U.**
Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis. Cancer 1996;78:1958-1966. EBM Ilb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8909317&dopt=Abstract
7. **Osterlind A, Berthelsen JG, Abildgaard N, Hansen SO, Hjalgrim H, Johansen B, Munck-Hansen J, Rassmussen LH.**
Risk of bilateral testicular germ cell tumors in Denmark: 1960-1984. J Natl Cancer Inst, 1991;83:1391-1395. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1656057&dopt=Abstract
8. **Moller H, Prener A, Skakkebaek NE.**
Testicular cancer, cryptorchidism, inguinal hernia, testicular atrophy and genital malformations: case-control studies in Denmark. Cancer Causes Control, 1996;7:264-274. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8740739&dopt=Abstract
9. **Dieckmann KP, Pichlmeier U.**
The prevalence of familial testicular cancer. Cancer, 1997;80:1954-1960. EBM Ilb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9366298&dopt=Abstract
10. **Forman D, Oliver RTD, Marsh SGE, et al.**
Familial testicular cancer: a report of the UK family register, estimation of risk and a HLA class 1 sib-pair analysis. Brit J Cancer, 1992;65:255-262. EBM Ilb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1739626&dopt=Abstract
11. **Weestergaard T, Olsen JH, Frisch M, Kroman N, Nielsen JW, Melbye M.**
Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population based study. Int J Cancer, 1996;66:627-631. EBM Ilb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8647624&dopt=Abstract
12. **Dieckmann KP, Loy V, Buttner P.**
Prevalence of bilateral germ cell tumors and early detection based on contralateral testicular intra-epithelial neoplasia. Br J Urol, 1993;71:340-345. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8386582&dopt=Abstract
13. **Dieckmann KP, Pichlmeier U.**
Is risk of testicular cancer related to the body size?. Eur Urol, 2002;42(6):564-569. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12477651&dopt=Abstract
14. **Wanderas EH, Tretli S, Fossa SD.**
Trends in incidence of testicular cancer in Norway 1955-1992. Eur J cancer, 1995;31A:2044-2048. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8562163&dopt=Abstract

15. **Jones A, Fergus JN, Chapman J, Houghton L.**
Is surveillance for stage I germ cell tumours of the testis appropriate outside a specialist centre?
NJU Int 1999;84:79-84. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10444129&dopt=Abstract
16. **Collette L, Sylvester RJ, Stenning SP, Fossa SD, Mead GM, de Wit R, de Mulder PH, Ney Lallemand E, Kaye SB.**
Impact of the treating institution on survival of patients with poor-prognosis non-seminoma.
European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Collaborative group and the Medical Research Council Testicular Working Party,
J Natl Cancer Inst 1999;91(10): 839-846. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10340903&dopt=Abstract
17. **Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H.**
Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis.
J Clin Oncol 2002;20(22):4448-4452. EBM IIIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12431967&dopt=Abstract
18. **Shelley MD, Burgon K, Mason MD.**
Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review.
Cancer Treatment Reviews 2002;28:237-253.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12435371&dopt=Abstract
19. **Krege S, Souchon R, Schmoll HJ; German Testicular Cancer Study Group.**
Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM). Eur Urol 2001;40:372-391.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11713391&dopt=Abstract
20. **Deutsche Krebsgesellschaft: Leitlinie zur Diagnostik und Therapie von Hodentumoren auf Grundlage evidenzbasierter Medizin (EBM). Souchon R, Schmoll HJ, Krege S, for the German Testicular Cancer Study Group (eds).**
Qualitätsicherung in der Onkologie. 1st ed. Munchen-Bern-Wien-New York-Zuckschwerdt, 2002.
21. **The Royal College of radiologist' Clinical Oncology Network in partnership with Scottish Intercollegiate Network 2000: Guidelines on the management of adult testicular germ cell tumours.**
Clin Oncol 2000;12:S173-S 210.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11315727&dopt=Abstract
22. **Diagnostiek en behandeling van kiemceltumoren van de testis. Richtlijnen Nederlandse Vereniging voor urologie. No 14.**
23. **Segal R, Lukka H, Klotz LH, Eady A, Bestic N, Johnston M; Cancer Care Ontario Practice Guidelines Initiative Genitourinary Cancer Disease Site Group.**
Surveillance programs for early stage non-seminomatous testicular cancer: a practice guideline.
Can J Urol 2001;8(11):1184-1192.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11268306&dopt=Abstract
24. **US Department of Health and Human services. Public Health Service, Agency for Health Care Policy and Research 1992; pp:115-127.**
<http://www.ahcpr.gov/>
25. **Mostofi FK, Sesterhenn IA. Histological typing of testis tumours. WHO International Histological Classification of Tumours, 2nd ed. Berlin-Heidelberg-New York-Tokyo, Springer, 1998.**
26. **Germa-Lluch JR, Garcia del Muro X, Maroto P, Paz-Ares L, Arranz JA, Guma J, Alba E, Satre J, Aparicio J, Fernandez A, Barnadas A, Terrassa J, Saenz A, Almenar D, Lopez-Brea M, Climent MA, Sanchez MA, Lasso de la Vega R, Berenguer G, Perez X; Spanish Germ-Cell Cancer Group (GG).**
Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 2002;42:553-562. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12477650&dopt=Abstract

27. **Skakkebaek EN.**
Possible carcinoma-in-situ of the testis. Lancet 1972; ii:516-517. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4115573&dopt=Abstract
28. **Richie JP, Birnholz J, Gamick MB.**
Ultrasonography as a diagnostic adjunct for the evaluation of masses in the scrotum. Surg Gynecol Obstet 1982;154:695-698. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7071705&dopt=Abstract
29. **Doherty FJ.**
Ultrasound of the nonacute scrotum. In: Seminars in Ultrasound, CT and MRI. Raymond HW et al. (eds). WB Saunders Co.: New York, 1991, 131-156.
30. **Comiter CU, Benson CJ, Capelouto CC, Kantoff P, Shulman L, Richie JP, Loughlin KR.**
Nonpalpable intratesticular masses detected sonographically. J Urol 1995;154:1367-1369. EBM III.
<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=PubMed>
31. **Friedrich M, Claussen CD, Felix R.**
Immersion ultrasound of testicular pathology. Radiology 1981;141:235-237.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7291531&dopt=Abstract
32. **Glazer HS, Lee JKT, Melson GL, McClennan BL.**
Sonographic detection of occult testicular neoplasm. Am J Roentgenol 1982;138:673-675.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6978030&dopt=Abstract
33. **Bockrath JM, Schaeffer AJ, Kiess MS, Nieman HL.**
Ultrasound Identification of Impalpable testicle tumor. J Urol 1983;130:355-356.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6876291&dopt=Abstract
34. **Shawker TH, Javadpour N, O'Leary T, Shapiro E, Krudy AG.**
Ultrasonographic detection of burned-out primary testicular germ cell tumors in clinically normal testes. J Ultrasound Med 1983;2:477-479.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6313958&dopt=Abstract
35. **Lenz S, Giwercman A, Skakkebaek NE, Bruun E, Fridodt-Moller C.**
Ultrasound in detection of early neoplasia of the testis. Int J Androl 1987;10:187-190. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2884185&dopt=Abstract
36. **Thurnher S, Hricak H, Carroll PR, Pobielski RS, Filly RA.**
Imaging the testis. Comparison between MR imaging and US. Radiology 1988;167:631-636.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3283834&dopt=Abstract
37. **Mattrey RF.**
Magnetic resonance imaging of the scrotum. Semin Ultrasound CT MR 1991;12:95-108.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1863480&dopt=Abstract
38. **Rholl KS, Lee JKT, Ling D, Heiken JP, Glazer HS.**
MR imaging of the scrotum with a high resolution surface coil. Radiology, 1987;163:99-103. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3547497&dopt=Abstract
39. **Johnson HO, Mattrey RF, Phillipson J.**
Differentiation of seminomatous from nonseminomatous testicular tumors by MRI. Am J Roentgenol 1990;154:539-543.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2106218&dopt=Abstract
40. **Klein EA.**
Tumor markers in testis cancer. Urol Clin North Am 1993;20:67-73.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7679533&dopt=Abstract
41. **Peyret C.**
Tumeurs du testicule. Synthèse et recommandations en onco-urologie. Prog Urol 1993;2:60-64.

42. **Javadpour N.**
The role of biologic markers in testicular cancer. *Cancer* 1980;45:1755-1761.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6154517&dopt=Abstract
43. **Heidenreich A, Weissbach L, Holth W, Albers P, Kliesch S, Kohrmann KU, Dieckmann KP.**
German Testicular Cancer Study Group. Organ sparing surgery for malignant germ cell tumor of the testis. *J Urol* 2001;166:2161-2165. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11696727&dopt=Abstract
44. **Heidenreich A, Holtl W, Albrecht W, Pont J, Engelmann UH.**
Testis preserving surgery in bilateral testicular germ cell tumors. *Br J Urol* 1997;79:253-257. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9052478&dopt=Abstract
45. **Weissbach L.**
Organ preserving surgery of malignant germ cell tumors. *J Urol* 1995;153:90-93. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7966800&dopt=Abstract
46. **Dieckmann KP, Loy V.**
Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasm. *J Clin Oncol* 1996;14:3126-3132. EBM IIa-IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8955658&dopt=Abstract
47. **Von der Maase H, Rorth M, Walbom-Jorgensen S, Sorensen BL, Christophersen IS, Hald T, Jacobsen GK, Berthelsen JG, Skakkebaek NE.**
Carcinoma-in-situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. *BMJ* 1986; 293:1398-1401. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3026550&dopt=Abstract
48. **Harland SJ, Cook PA, Fossa SD, Horwich A, Mead GM, Parkinson MC, Roberts JT, Stenning SP.**
Intratubular germ cell neoplasia of contralateral testis in testicular cancer: defining high risk group. *J Urol* 1998;160:1353-1357. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9751353&dopt=Abstract
49. **Giwercman A, Bruun E, Frimotd-Muller C, Skakkebaek NE.**
Prevalence of carcinoma in situ and other histopathological abnormalities in testes of men with a history of cryptorchidism. *J Urol* 1989;142:998-1002. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2571738&dopt=Abstract
50. **Tabernerero J, Paz-Ares L, Salazar R, Lianes P, Guerra J, Borrás J, Villavicencio H, Leiva O, Cortes-Funes H.**
Incidence of contralateral germ cell testicular tumors in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature. *J Urol* 2004;171:164-167. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14665868&dopt=Abstract
51. **Herr HW, Sheinfeld J.**
Is biopsy of the contralateral testis necessary in patients with germ cell tumors?
J Urol 1997;158:1331-1334.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9302113&dopt=Abstract
52. **Albers P, Goll A, Bierhoff E, Schoeneich G, Muller SC.**
Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumors. *Urology* 1999;54:714-718.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10510934&dopt=Abstract
53. **Heidenreich A, Moul JW.**
Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated?
Sem Urol Oncol 2002;20(4):234-238. EBM III or IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12489055&dopt=Abstract

54. **Leibovitch I, Foster RS, Kopecky KK, Donohue JP.**
Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 1995;154:1759-1763. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7563341&dopt=Abstract
55. **Jing B, Wallace S, Zornoza J.**
Metastases to retroperitoneal and pelvic lymph nodes: computed tomography and lymphangiography. Radiol Clin North Am 1985;20:511-530.
56. **Husband JE, Barrett A, Peckham MJ.**
Evaluation of computed tomography in the management of testicular teratoma. Br J Urol 1981; 53:179-183. EBM III.
57. **Swanson DA.**
Role of retroperitoneal lymphadenectomy (RLDN) when patients with nonseminomatous germ cell testicular tumors are at high risk of needing lymph node surgery plus chemotherapy. In: Lymph Node Surgery in Urology. International Society of Urology Reports. Donohue JP(ed.). Isis Medical Media: Oxford, 1995, 133-140.
<http://www.isismedical.com>
58. **Ellis JH, Blies JR, Kopecky KK, Klatte EC, Rowland RG, Donohue JP.**
Comparison of NMR and CT imaging in the evaluation of metastatic retroperitoneal lymphadenopathy from testicular carcinoma. J Comput Assist Tomogr 1984;8:709-719.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6539790&dopt=Abstract
59. **See WA, Hoxie L.**
Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results. J Urol 1993;150:874-878. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8345604&dopt=Abstract
60. **Cremerius U, Wildberger JE, Borchers H, Zimny M, Jakse G, Gunther RW, Buell U.**
Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?- results of a study in 50 patients. Urology 1999;54:900-904. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10565755&dopt=Abstract
61. **Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC.**
Positron emission tomography in the clinical staging of patients with Stage I and II testicular Germ Cell tumors. Urology 1999;53:808-811. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10197862&dopt=Abstract
62. **De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K, Dohmen BM, Dittrich C.**
Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001;19:3740-3744. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11533096&dopt=Abstract
63. **Spermon JR, De Geus-Oei LF, Kiemeny LA, Witjes JA, Oyen WJ.**
The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int, 2002, 89: 549-556. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11942962&dopt=Abstract
64. **Sobin LH, Wittekind Ch (eds).**
UICC: TNM Classification of malignant tumours. Sixth edition, 2002. Wiley-Liss, Inc.
www.wiley.com/go/tnm
65. **Zagars GK.**
Management of stage I seminoma: radiotherapy. In: Testicular Cancer: Investigation and Management. Horwich A (ed.): Chapman & Hall Medical: London, 1999, 99.
66. **Klepp O, Flodgren P, Maartman-Moe H, Lindholm CE, Unsgaard B, Teigum H, Fossa SD, Paus E.**
Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchietomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA). Ann Oncol 1990; 1:281-288. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1702312&dopt=Abstract

67. **International Germ Cell Cancer Collaborative Group.**
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. *J Clin Oncol* 1997;15:594-603. EBM Ia,Ila, IIb, III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9053482&dopt=Abstract
68. **Bokemeyer C, Schmoll HJ.**
Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters. *J Cancer Res Clin Oncol* 1996;122:575-584.
69. **Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, Achulze H, Heidenreich A, de Riese W, Loy V, Bierhoff E, Wittekind C, Fimmers R, Hartmann M; German Testicular Cancer Study Group.**
Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. *J Clin Oncol* 2003;21(8):1505-1512. EBM IIa-Ib.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12697874&dopt=Abstract
70. **Petersen PM, Giwercman A, Skakkebaek NE, Rorth M.**
Gonadal function in men with testicular cancer. *Semin Oncol* 1998;25:224-233. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9562456&dopt=Abstract
71. **Petersen PM, Giwercman A, Daugaard G, Rorth M, Petersen JH, Skakkebaek NE, Hansen SW, von der Maase H.**
Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. *J Clin Oncol* 2002;20:1537-1543. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11896102&dopt=Abstract
72. **De Santis M, Albrecht W, Holtl W, Pont J.**
Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. *Int J cancer* 1999; 83: 864-865. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10597213&dopt=Abstract
73. **Jacobsen KD, Fossa SD, Bjoro TP, Aass N, Heilo A, Stenwig AE.**
Gonadal function and fertility in patients with bilateral testicular germ cell malignancy. *Eur Urol* 2002;42: 229-238. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12234507&dopt=Abstract
74. **Kliesch S, Behre HM, Jurgens H, Nieschlag E.**
Cryopreservation of semen from adolescent patients with malignancies. *Med Pediatr Oncol* 1996;26:20-27. EBM IV.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7494508&dopt=Abstract
75. **Giwercman A, von der Maase H, Rorth M, Skakkebaek NE.**
Semen quality in testicular tumour and CIS in the contralateral testis. *Lancet* 1993;341:384-385. EBM IV.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8094162&dopt=Abstract
76. **Kliesch S, Bergmann M, Hertle L, Nieschlag E, Behre HM.**
Semen parameters and testicular pathology in men with testicular cancer and contralateral carcinoma in situ or bilateral testicular malignancies. *Hum Reprod* 1997;12:2830-2835. EBM IV.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9455863&dopt=Abstract
77. **Spermon JR, Kiemeny LA, Meuleman EJ, Ramos L, Wetzels AM, Witjes JA.**
Fertility in men with testicular germ cell tumors. *Fertil Steril* 2003; 79, suppl 3:1543-1549. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12801557&dopt=Abstract
78. **Nieschlag E, Behre HM.**
Pharmacology and clinical use of testosterone. In: Nieschlag E, Behre HM eds. *Testosterone-Action, deficiency, substitution*. Berlin –Heidelberg–New York, Springer,1999.pp: 92-114. EBM Ib-IV.

7 TREATMENT: STAGE I GERM CELL TUMOURS

7.1 Stage I seminoma

After modern staging procedures, about 15-20% of stage I seminoma patients have subclinical metastatic disease, usually in the retroperitoneum, and will relapse after orchiectomy alone (1).

7.1.1 Prophylactic radiotherapy

Seminoma cells are extremely radiosensitive. Prophylactic radiotherapy to a para-aortic (PA) field or to a hockey stick field (para-aortic and ipsilateral iliacal nodes), with moderate doses (total 20-24 Gy), will reduce the relapse rate to only 1-3% (2-5). After modern radiotherapy nearly all relapses will first occur outside the irradiated field (supradiaphragmatic lymph nodes or in the lungs) (2,5). Based upon the results of a large randomized Medical Research Council (MRC) trial, Fossa et al. (2,3) recommended radiotherapy to a para-aortic field as standard treatment for patients with testicular seminoma stage I, T1-T3 and with undisturbed lymphatic drainage. The acute toxicity was reduced and the sperm count within the first 18 months was significantly higher after para-aortic irradiation than after irradiation of the traditional dog-leg field. On the other hand, the relapse rate in the iliac lymph nodes was about 2% (all of them on the right side) after para-aortic and 0% after dog-leg irradiation. Another possible site of failure is in the left renal hilum. Para-aortic irradiation should be tailored according to the site of the primary tumour. Prophylactic irradiation of supradiaphragmatic lymph nodes is not indicated in seminoma stage I.

The rate of severe radiation-induced long-term toxicity is less than 2%. Moderate chronic gastrointestinal (GI) side-effects are seen in about 5% of patients and moderate acute GI toxicity in about 60% (2). The main concern surrounding prophylactic radiotherapy is the potentially increased risk of radiation-induced secondary non-germ-cell malignancies, including leukaemia (6-8). A scrotal shield can be of benefit during prophylactic radiotherapy in order to prevent scattered radiation toxicity in the contralateral testis (9), but this is not needed for a para-aortic field. At this point in time it is difficult to evaluate the long-term risks after prophylactic radiotherapy for stage I seminoma since former treatment procedures included larger fields, higher doses of radiotherapy and/or the use of alkylating chemotherapy.

7.1.2 Surveillance

Several prospective non-randomized studies of surveillance have been conducted during the last decade, several of which comprised more than 100 patients. Meta-analysis from the 4 largest studies shows an actuarial 5 years relapse-free rate of 82.3%. On multivariate analysis tumor size (< or = 4 cm) and invasion of the rete testis remained as the most important predictors for relapse (10)

The actuarial relapse rate is of the order of 15-20% at 5 years, and most of the relapses are first detected in infra-diaphragmatic lymph nodes (1,11-13). About 70% of the patients relapsing after surveillance are suitable for treatment with radiotherapy alone. Only about 20% of these patients relapse after salvage radiotherapy and need salvage chemotherapy. The overall cancer-specific survival rate reported by experienced centres is 97-100% for seminoma stage I after surveillance (12,13). A pooled (multivariate) analysis based on the three largest studies of testicular seminoma stage I managed by surveillance indicates that a primary tumour of over 4 cm in size and invasion of the rete testis are important prognostic factors for relapse, with hazard ratios of 1.9 and 2.0, respectively (10). The main drawback of surveillance is the need for more intensive follow-up, especially with repeated imaging examinations of the retroperitoneal lymph nodes, for at least 5 years after orchiectomy. This compares with the very low risk of subdiaphragmatic relapse after prophylactic radiotherapy. About 20% of the relapses seen after surveillance occur more than 4 years after orchiectomy (12). Cost analyses of surveillance compared with radiotherapy indicate that it is more expensive (14), but estimates vary depending basically on the follow-up schedules (15,16).

7.1.3 Prophylactic chemotherapy

Chemotherapy is very effective in advanced seminoma and may be an alternative to radiotherapy or surveillance in stage I seminoma (12,13). One or two courses of adjuvant carboplatin seem to reduce the relapse rate to the order of 1-3% (13,17,18), but further experience and long-term observations are needed before such adjuvant chemotherapy can be recommended as a routine option. A joint MRC and EORTC trial (MRC TE 19 trial) is currently comparing adjuvant radiotherapy with one course of carboplatin, but the results are not yet available (2).

7.1.4 Retroperitoneal Lymph Node Dissection (RPLND)

In a prospective, non-randomized study comparing radiotherapy and RPLND in stage I seminoma, there was a trend towards a higher incidence of retroperitoneal relapses (9.5%) after RPLND as primary treatment. Therefore this policy should not be recommended in stage I seminoma (17).

7.2 GUIDELINES FOR THE TREATMENT OF SEMINOMA STAGE 1

1. Prophylactic radiotherapy to a para-aortic or a hockey stick field, to a total dose of 20-24 Gy. (GRADE A recommendation)
2. Surveillance (if available facilities). (GRADE B recommendation)
3. Awaiting the results of current comparative studies, Carboplatin based chemotherapy can only be recommended in the setting of clinical trials. (GRADE B recommendation)

7.3 NSGCT stage I

If stage IS cases are excluded, up to 30% of NSGCT patients with clinical stage I (CS1) disease have subclinical metastases and will relapse if surveillance alone is applied after orchiectomy.

7.3.1 RPLND

If RPLND is performed, about 30% of patients are found to have retroperitoneal lymph node metastases, which corresponds to pathological stage II (PS2) disease (18-20). If no retroperitoneal metastases are found at RPLND (PS1), approximately 10% of the PS1 patients relapse at distant sites (21-25).

The main predictor of relapse in CS1 NSGCT managed by surveillance, and both for having PS2 disease and for relapse in PS1 after RPLND, is histopathological evidence of vascular invasion by tumor cells in, or near, the primary tumor in the testis (22,24-27). The presence of vascular invasion seems to be a very robust parameter, and is clinically usable even without centralized review by an expert panel (24,28). Vascular invasion was the most predictive of stage in a multifactorial analysis. The absence of vascular invasion has a negative predictive value of 77%, thus allowing for surveillance in low-risk compliant patients (25)

Patients without vascular invasion constitute about 50- 70% of the CS1 population, and these patients have only a 15-20% risk of relapse on surveillance, compared with a 50% relapse rate in patients with vascular invasion. The risk of relapse for PS1 patients is less than 10% for those without vascular invasion and about 30% for those with vascular invasion (24,28-30).

If CS1 patients with PS2 are only followed up after RPLND, about 30% relapse, mainly at sites outside the abdomen and pelvis. The risk of relapse depends upon the amount of retroperitoneal disease resected (31-33). If two (or more) courses of cisplatin-based chemotherapy are given adjuvant to RPLND in the PS2 cases, the relapse rate is reduced to less than 2%, including teratoma relapse (22,26,34). The risk of retroperitoneal relapse after a properly performed nerve-sparing RPLND is very low (less than 2%), as is the risk of ejaculatory disturbance or other significant side-effects (26,31,32). The follow-up after RPLND is much simpler and less costly than that carried out during post-orchiectomy surveillance due to the reduced need for abdominal CT scans (26). A laparoscopic RPLND may become a good alternative to an open RPLND, but can currently not be recommended as a standard treatment (35-38).

7.3.2 Surveillance

Improvements in clinical staging and follow-up methods, and the availability of effective salvage treatment with cisplatin-based chemotherapy and post-chemotherapy surgery, have led to studies of only close surveillance after orchiectomy in CS1 NSGCT patients. The largest reports of the surveillance strategy indicate a cumulative relapse rate of about 30%, with 80% of the relapses occurring during the first 12 months of follow-up, 12% during the second year and 6% during the third year, decreasing to 1% during the fourth and fifth years, and occasionally even later (27,39,40). About 35% of relapsing patients have normal levels of serum tumour markers at relapse. About 60% of the relapses are in the retroperitoneum. Despite very close follow-up, 11% of relapsing patients presented with large-volume recurrent disease. The somewhat lower relapse rates reported from surveillance studies compared with some series of patients staged by RPLND (22) can be explained by the fact that some patients (presumably at risk) are excluded once surveillance is advised.

7.3.3 Primary chemotherapy

Several studies involving two courses of chemotherapy with bleomycin, etoposide and cisplatin, (BEP) as primary treatment for high-risk patients (having about 50% risk of relapse) have been reported (41-45). In these series, involving more than 200 patients, some with a median follow-up of nearly 8 years (41), a relapse rate of only 2.7% was reported, with very little long-term toxicity. Two cycles of cisplatin based adjuvant chemotherapy do not seem to adversely affect fertility or sexual activity (46). It is important to be aware of the risk of slow-growing retroperitoneal teratomas after primary chemotherapy and of the risk of chemoresistant cancer relapse. The need for repeated and long-term follow-up with imaging (CT or ultrasound) of the retroperitoneum after primary chemotherapy is not yet clear. The results of cost analyses comparing surveillance, RPLND and primary chemotherapy show different results among the reported studies, possibly because of differences in intensity and costs related to follow-up procedures. Overall costs for the different options in treating CS1 may be of the same order of magnitude although a unique cost-benefit analysis shows that adjuvant chemotherapy is the cheaper option per life saved (14-16,47).

7.3.4 Risk-adapted treatment

As with primary chemotherapy, a policy of stratifying patients with CS1 NSGCT according to their presumed risk of relapse may be a rational option. Several studies have reported similar survival rates and a final cure rate close to 100% (28,41-44,48). The main selection criterion for high-risk patients was the presence of vascular invasion in those treated with primary chemotherapy or RPLND, and that for low-risk patients was the absence of vascular invasion following surveillance.

7.4 CS1S with (persistently) elevated serum tumour markers

Serum tumour markers should be followed closely until it is clear whether or not levels are falling according to the expected half-time values for AFP and beta-hCG. If the marker level increases after orchiectomy, the patient has residual disease. If RPLND is performed, up to 87% of these patients have pathologically documented nodes in the retroperitoneum (49). An ultrasound examination of the contralateral testicle must be performed, if this has not been done initially.

The treatment of true CS1S patients is still controversial. They may be treated with either three courses of primary BEP chemotherapy, with follow-up as for CS1B (high risk; see below) patients after primary chemotherapy (50), or by RPLND (47). The presence of vascular invasion may strengthen the indication for primary chemotherapy as most CS1S with vascular invasion will need chemotherapy sooner or later anyway.

7.5 GUIDELINES FOR THE TREATMENT OF NSGCT STAGE I

CS1A (pT1, no vascular invasion); low risk

1. If the patient is willing and able to comply with a surveillance policy and long-term (at least 5 years) close follow-up is feasible; surveillance is equivalent to nerve-sparing RPLND (GRADE B recommendation)
2. If RPLND reveals PN+ (nodal involvement) disease, we are facing a Pathological Stage II and consequently adjuvant chemotherapy with two courses of BEP should be considered (GRADE A recommendation)

CS1B (pT2-pT4); high risk

One of the following active treatments is recommended:

1. Nerve-sparing RPLND, which must be bilateral if PN+ disease is revealed perioperatively (nerve-sparing on the opposite side). If Pathological Stage II is revealed further chemotherapy should be Considered (GRADE A recommendation)
2. Primary chemotherapy with two courses of BEP (GRADE B recommendation).

7.6 REFERENCES (Treatment Stage I Testis Tumor)

1. **Sternberg CN.**
The management of stage I testis cancer. *Urol Clin North Am.* 1998 Aug;25(3):435-49. EBM Ib.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9728213&dopt=Abstract&itool=iconabstr
2. **Fossa SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ, Jones WG, Yosef H, Duchesne GM, Owen JR, Grosch EJ, Chetiyawardana AD, Reed NS, Widmer B, Stenning SP.**
Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. *J Clin Oncol* 1999;17:1146-1154. EBM Ib.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10561173&dopt=Abstract&itool=iconabstr
3. **Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Naylor S, Tenning SP.**
A randomized trial of two radiotherapy schedules in the adjuvant treatment of stage I seminoma (MRC TE 18). *E J Cancer* 2001;37(1) abstract book: S 157, abstract 572. EBM Ib.
4. **Melchior D, Hammer P, Fimmers R, Schuller H, Albers P.**
Long term results and morbidity of paraaortic compared with paraaortic and iliac adjuvant radiation in clinical stage I seminoma. *Anticancer Res* 2001;21:2989-2993. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11712799&dopt=Abstract&itool=iconabstr
5. **Livsey JE, Taylor B, Mobarek N, Cooper RA, Carrington B, Logue PJ.**
Patterns of relapse following radiotherapy for stage I seminoma of the testis: implications for follow-up. *Clin Oncol (R Coll Radiol)* 2001; 13: 296-300. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11554630&dopt=Abstract&itool=iconabstr

6. **Van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, Noyon R, Eliel MR, van Kerkhoff EH, Delemarre JF, Somers R.**
Second cancer risk following testicular cancer: a follow-up study of 1909 patients. Clin Oncol 1993;11:415- 424.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8445415&dopt=Abstract&itool=iconabstr
7. **Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, Kohler BA, Pukkala E, Lynch CF, Andersson M, Bergfeldt K, Clarke EA, Wiklund T, Stoter G, Gospodarowicz M, Sturgeon J, Fraumeni JF Jr, Boice JD Jr.**
Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429-1439. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9326912&dopt=Abstract&itool=iconabstr
8. **Horwich A, Bell J.**
Mortality and cancer incidence following treatment for seminoma of the testis. Radiother Oncol 1994; 30: 193-198. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8209001&dopt=Abstract&itool=iconabstr
9. **Bieri S, Rouzaud M, Miralbell R.**
Seminoma of the testis: is scrotal Shielding necessary when radiotherapy is limited to the para-aortic nodes? Radiother Oncol 1999;50:349-353. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10392822&dopt=Abstract&itool=iconabstr
10. **Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H.**
Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol, 2002; 20(22): 4448-4452. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12431967&dopt=Abstract&itool=iconabstr
11. **Chung P, Parker C, panzarella T, Gospodarowicz MK, Jewett S, Milosevic MF, Catton CN, Bayley AJ, Tew-George B, Moore M, Sturgeon JF, Warde P.**
Surveillance in stage I testicular seminoma-risk of late relapse. Can J Urol 2002;9(5):1637-1640. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12431325&dopt=Abstract&itool=iconabstr
12. **Warde P, Jewett MAS.**
Surveillance for stage I testicular seminoma. Is it a good option? Urol Clin North Am 1998;25: 425-433.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9728212&dopt=Abstract&itool=iconabstr
13. **Aparicio J, Garcia del Muro X, Maroto P, Paz-Ares L, Alba E, Saenz A, Terrasa J, Barnadas A, Almenar D, Arranz JA, Sanchez M, Fernandez A, Sastre J, Carles J, Dorca J, Guma J, Yuste AL, Germa JR; Spanish Germ Cell Cancer Cooperative Group (GG).**
Multicenter study evaluating a dual policy of postorchietomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 2003,14:867-872.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12796024&dopt=Abstract&itool=iconabstr
14. **Sharda N, Kinsella T, Ritter M.**
Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early-stage testicular seminoma. J Clin Oncol 1996;14:2933-2939. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8918490&dopt=Abstract&itool=iconabstr
15. **Francis R, Bower M, Brunstrom G, Holden L, Newlands ES, Rustin GJS, Seckl MJ.**
Surveillance for stage I testicular germ cell tumors: results and cost benefit analysis of management options. European Journal of Cancer 2000;36:1925-1932. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11000572&dopt=Abstract&itool=iconabstr
16. **Warde P, Gospodarowicz M, Panzarella T, Catton C, Sturgeon J, Moore M, Jewett M.**
Issues in the management of stage I testicular seminoma. Int JRadiat Oncol Biol Phys 1997;39: S156.

17. **Warszawski N, Schmucking M.**
Relapses in early-stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy. *Scan J Urol Nephrol* 1997;31:335-339. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9290165&dopt=Abstract&itool=iconabstr
18. **Heidenreich A, Albers P, Hartmann M, Kliesch S, Kohrmann KU, Krege S, Lossin P, Weissbach L; German Testicular Cancer Study Group.**
Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. *J Urol* 2003; 169(5):1710-1714. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12686815&dopt=Abstract&itool=iconabstr
19. **Spermon JR, Roeleveld TA, van der Poel HG, Hulsbergen-van de Kaa CA, Ten Bokkel-Huinink WW, van de Vijver M, Witjes JA, Horenblas S.**
Comparison of surveillance and retroperitoneal lymph node dissection in stage I nonseminomatous germ cell tumors. *Urology* 2002;59:923-929. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12031382&dopt=Abstract&itool=iconabstr
20. **Hendry WF, Norman A, Nicholls J, Dearnaley DP, Peckham MJ, Horwich A.**
Abdominal relapse in stage 1 nonseminomatous germ cell tumours of the testis managed by surveillance or with adjuvant chemotherapy. *BJU Int* 2000;86:89-93. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10886090&dopt=Abstract&itool=iconabstr
21. **Pizzocaro G, Salvioni R, Zanoni F.**
Unilateral lymphadenectomy in intraoperative stage I nonseminomatous testis cancer. *J Urol* 1985;134:485-489. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2993672&dopt=Abstract&itool=iconabstr
22. **Klepp O, Olsson AM, Henrikson H, Aass N, Dahl O, Stenwig AE, Persson BE, Cavallin-Stahl E, Fossa SD, Wahlqvist L.**
Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. *J Clin Oncol* 1990;8:509-518. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1689773&dopt=Abstract&itool=iconabstr
23. **Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihle R.**
Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965-1989): modifications of technique and impact on ejaculation. *J Urol* 1993;149:237-243. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8381190&dopt=Abstract&itool=iconabstr
24. **Lashley DB, Lowe BA.**
A rational approach to managing stage I nonseminomatous germ cell cancer. *Urol Clin North Am* 1998;25:405-423.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9728211&dopt=Abstract&itool=iconabstr
25. **Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, Achulze H, Heidenreich A, de Riese W, Loy V, Bierhoff E, Wittekind C, Fimmers R, Hartmann M; German Testicular Cancer Study Group.**
Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. *J Clin Oncol* 2003; 21(8):1505-1512. EBM IIa-Ib.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12697874&dopt=Abstract&itool=iconabstr
26. **Foster RS, Roth BJ.**
Clinical stage I nonseminoma: surgery versus surveillance. *Semin Oncol* 1998;25:145-153.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9562447&dopt=Abstract&itool=iconabstr

27. **Freedman LS, Parkinson MC, Jones WG, Oliver RT, Peckham MJ, Read G, Newlands ES, Williams CJ.**
Histopathology in the prediction of patients with stage I testicular teratoma treated by orchiectomy alone. *Lancet* 1987; ii: 294-298.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2886764&dopt=Abstract&itool=iconabstr
28. **Klepp O, Dahl O, Flodgren P, Stierner U, Olsson AM, Oldbring J, Nilsson S, Daehlin L, Tornblom M, Smaland R, Starkhammar H, Abramsson L, Wist E, Raabe N, Edekling T, Cavallin-Stahl E.**
Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer.
Eur J Cancer 1997;33: 1038-1044. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9376184&dopt=Abstract&itool=iconabstr
29. **Kratzick C, Hottl W, Albrecht W et al.**
Risk adapted management for NSGCT stage I: long-term results of a multicenter study.
J Urol 1996;155:547A. (Abstract).
30. **Ondrus D, Goncalves F, Kausitz J, Mat'oska J, Belan V.**
The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors (NSGCTT). *Neoplasma* 1996;43:195-197.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8841507&dopt=Abstract&itool=iconabstr
31. **Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrl R.**
Clinical stage B nonseminomatous germ cell testis cancer: the Indiana University experience using routine primary retroperitoneal lymph node dissection. *Eur J Cancer* 1995;31A:1599-1604. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7488408&dopt=Abstract&itool=iconabstr
32. **Richie JP, Kantoff PW.**
Is adjuvant chemotherapy necessary for patients with stage 1B testicular cancer?
J Clin Oncol 1991;9:1393-1398.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2072143&dopt=Abstract&itool=iconabstr
33. **Pizzocaro G, Monfardini S.**
No adjuvant chemotherapy in selected patients with pathological stage II nonseminomatous germ cell tumors of the testis. *J Urol* 1984;131:677-680. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6200611&dopt=Abstract&itool=iconabstr
34. **Williams SD, Stablein DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP, Paulson DF, Brunner KW, Jacobs EM, Spaulding JT.**
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. *N Engl J Med* 1987;317:1433-1438. EBM Ib.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2446132&dopt=Abstract&itool=iconabstr
35. **Bianci G, Beltrami P, Giusti G.**
Unilateral laparoscopic lymph node dissection for clinical stage I nonseminomatous germ cell testicular neoplasm. *Eur Urol* 1998; 33:190-194. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9519363&dopt=Abstract&itool=iconabstr
36. **Rassweiler JJ, Frede T, Lenz E, Seemann O, Alken P.**
Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low- stage testis cancer. *Eur Urol* 2000;37:251-260. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10720848&dopt=Abstract&itool=iconabstr
37. **Janetschek G, Hobisch A, Peschel R, Hittmair A, Bartsch G.**
Laparoscopic retroperitoneal lymph node dissection for clinical stage I non-seminomatous testicular carcinoma: long-term outcome. *J Urol* 2000;163:1793-1796. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10799184&dopt=Abstract&itool=iconabstr

38. **LeBlanc E, Caty A, Dargent D, Querleu D, Mazeman E.**
Extraperitoneal laparoscopic para-aortic lymph node dissection for early stage nonseminomatous germ cell tumors of the testis with introduction of a nerve sparing technique: description and results. J Urol 2001;165:89-92. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11125371&dopt=Abstract&itool=iconabstr
39. **Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, Cook PA.**
Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992;10:1762-1768. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1403057&dopt=Abstract&itool=iconabstr
40. **Colls BM, Harvey VJ, Skelton L, Frampton CM, Thompson PI, Bennett M, Perez DJ, Dady PJ, Forgeson GV, Kennedy IC.**
Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand. B J Urol Int 1999;83:76-82. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10233456&dopt=Abstract&itool=iconabstr
41. **Cullen MH, Stenning SP, Parkinson MC, Fossa SD, Kaye SB, Horwich AH, Harland SJ, Williams MV, Jakes R.**
Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumours of the testis: a Medical Research Council report. J Clin Oncol 1996;14:1106-1113. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8648364&dopt=Abstract&itool=iconabstr
42. **Oliver RTD, Raja MA, Ong J, Gallagher CJ.**
Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage I malignant teratoma on overall relapse rate of stage I cancer patients. J Urol 1992;148:1453-1456. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1279211&dopt=Abstract&itool=iconabstr
43. **Studer UE, Fey MF, Calderoni A.**
Adjuvant chemotherapy after orchiectomy in high risk patients with clinical stage I nonseminomatous testicular cancer. Eur Urol 1993;23:444-449. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7687549&dopt=Abstract&itool=iconabstr
44. **Bohlen D, Borner M, Sonntag RW, Fey MF, Studer UE.**
Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 1999;161:1148-1152. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10081858&dopt=Abstract&itool=iconabstr
45. **Pont J, Albrecht W, Postner G, Sellner F, Angel K, Holtl W.**
Adjuvant chemotherapy for high risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996;14:441-448. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8636755&dopt=Abstract&itool=iconabstr
46. **Bohlen D, Burkhard FC, Mills R, Sonntag RW, Studer UE.**
Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol 2001;165:441-444. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11176393&dopt=Abstract&itool=iconabstr
47. **Baniel J, Roth BJ, Foster RS, Donohue JP.**
Cost and risk benefit considerations in the management of clinical stage I nonseminomatous testicular tumors. Ann Surg Oncol 1996;3:86-93.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8770308&dopt=Abstract&itool=iconabstr
48. **Ondrus D, Matoska J, Belan V.**
Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. Eur Urol 1998;33:562-566. EBM IIa,IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9743698&dopt=Abstract&itool=iconabstr

49. **Pizzocaro G, Nicolai N, Salvioni R.**
Marker positive clinical stage I non seminomatous germ cell tumors (NSGCT) of the testis: which primary therapy? J Urol 1996;155(Suppl):328A.
50. **Davis BE, Herr HW, Fair WR, Bosl GJ.**
The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol 1994;152:111-113. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7515445&dopt=Abstract&itool=iconabstr

8 TREATMENT: METASTATIC GERM CELL TUMOURS

Treatment of metastatic germ cell tumours depends on:

- Histology of the primary tumour
- Prognostic groups as they have been defined by the International Germ Cell Cancer Collaborative Group (IGCCCG) based on 5,202 non-seminoma and 660 seminoma cases (Table 3) (1).

There is a general consensus that treatment should start with initial chemotherapy in all cases except for low-volume stage II disease, which alternatively can be treated with primary bilateral RPLND for non-seminoma (eventually followed by two cycles of chemotherapy or by surveillance) or radiotherapy for pure seminoma (2,3). In stage II a-b NSGCT primary chemotherapy and primary RPLND are comparable options in terms of outcome but side effects and toxicity are different, allowing for involvement of the patient in selecting the treatment of choice (4).

8.1 Primary chemotherapy

The primary treatment of choice for advanced disease is four courses of BEP (or PEB) combination chemotherapy (Table 5). These regimens have proven superiority to cisplatin, vinblastine and bleomycin (PVB) in patients with advanced disease (5,6,7).

Table 5: British BEP and PEB regimens (every 3 (4) weeks)

Drug	BEP	PEB
Cisplatin	20 mg/m ² , days 1–5 ^a	
Etoposide	120 mg/m ² , days 1, 3, 5	100 mg/m ² , days 1–5
Bleomycin	30 mg, days 2, 9, 16	

BEP = bleomycin, etoposide and cisplatin; PEB = cisplatin, etoposide and bleomycin.

^a Plus hydration.

For patients with a 'good prognosis', according to the International Germ Cell Cancer Consensus Classification (IGCCCG) (1) standard treatment consists of three cycles of PEB or in case of contraindication against bleomycin of four cycles of PE (1,8-11). Therapy should be given without reduction of the doses in 22-day intervals; delaying the following chemotherapy cycle is justified only in case of fever with granulocytopenia < 1,000/mm³ or thrombopenia < 100,000/ul. There is no indication for prophylactic application of hematopoietic growth factors as G-CSF for example. However, if infectious complications have occurred under chemotherapy, prophylactic administration of G-CSF is recommended for the following cycles (10,12).

With the 'intermediate prognosis' group in the IGCCC a group of patients has been defined, which reaches a 5-year survival rate of about 80%. The available data support four cycles of PEB as standard treatment (1,13). Due to the generally less favourable prognosis of this patient group, in comparison to patients with 'good prognosis', they may be treated in prospective trials like for example in the EORTC GU Group trial with PEB vs PEB+Paclitaxel (13).

For patients with 'poor prognosis' standard treatment consists of four cycles of PEB; four cycles of PEI (Cisplatin, Etoposide, Ifosfamide) are of the same effect but more toxic (14,15). The 5-year progression-free survival is between 45 and 50%. It has not yet been proven that high-dose chemotherapy increases the survival rate (16,17). Since a matched-pair analysis resulted in a better survival rate (18,19), these patients should be treated in the ongoing prospective randomized trial, investigating the value of high-dose chemotherapy. Patients meeting 'poor-prognosis' criteria should therefore be transferred to a reference

centre. Any general recommendations for treatment modifications for patients with a poor general condition (Karnofsky <50%), extended liver infiltration (>50%) and extended pulmonary infiltration do not exist.

8.2 Restaging and further treatment

8.2.1 Restaging

After termination of two courses of chemotherapy, re-evaluation is performed by imaging investigations and determination of tumor markers. At marker decline and stable or regressive tumor manifestation chemotherapy will be completed (three or four cycles depending on the initial stage) (1,20,21). In case of marker decline, but growing metastases, resection of the tumor is obligatory after termination of induction therapy, unless in case of emergency according to local tumor growth (22).

Only with documented marker growth after 2 courses of chemotherapy an early crossover of therapy is indicated. These patients are usually candidates for new drugs trials (19,23). Patients with a low-level marker plateau post treatment will be observed whether or not complete normalisation occurs. Salvage chemotherapy is indicated for documented marker rise only (24,25).

8.2.2 Residual tumor resection

A residual mass of seminoma will not be resected, irrespective of the size, but controlled by imaging investigations and tumor markers (26-32). On progression, salvage chemotherapy will be given, if necessary including surgery and radiotherapy (33-37). In case of non-seminoma and complete remission after chemotherapy, secondary RPLND is not indicated (38-43). In case of residual mass (greater than 1 cm in diameter) and marker normalisation surgical resection is indicated (38,44-51). Overall, following BEP induction chemotherapy, only 10% of residual masses contain viable cancer, 50% contain mature teratoma and 40% contain necrotic-fibrotic tissue. As yet no imaging investigation including PET or prognosis model are able to predict histological differentiation of the residual tumor. Residual tumor resection is mandatory (39-41,52-60).

The extent of surgery should be based on the risk of relapse of an individual patient and in quality of life issues (45). If possible, all the masses have to be resected because a complete resection, in the setting of viable malignant cells, is more critical than recourse to postoperative chemotherapy (61). Histology in different organ sites may diverge (53).

8.2.3 Consolidation chemotherapy after secondary surgery

After resection of necrosis or mature teratoma no further treatment is required. In case of complete resection of vital carcinoma or immature teratoma two adjuvant cycles of conventionally dosed cisplatin-based chemotherapy should be given (cave: cumulative doses of bleomycine). The prognosis will definitely deteriorate if vital carcinoma is found in resection specimens after second and third line chemotherapy. In this latter situation postoperative chemotherapy is not indicated and unable to improve the prognosis (49,54).

Two courses of cisplatin, vinblastine and bleomycine (PVB), vinblastine, adriamycin and, bleomycine (VAB) or BEP given post-operatively following lymphadenectomy for 'radically' resected retroperitoneal metastases containing viable cancer have been followed by nearly no relapses (62-66). This adjuvant treatment has been questioned by some authors (63-67), who reported equivalent results in 60 radically resected patients with, or without, such treatment. Furthermore, it has been demonstrated in a co-operative retrospective study (68) that the major success factors in these patients are complete surgical resection and percentage of viable cancer in the residual mass, with the effect of adjuvant chemotherapy being borderline. Nevertheless, the results with adjuvant chemotherapy are not statistically superior to those resulting from very careful observation and deferred treatment in the case of relapse (69).

8.3 Systemic salvage treatment for relapse or refractory disease

8.3.1 Seminoma

Cisplatin based combination salvage chemotherapy will result in long-term remissions for about 50% of patients who relapse after first-line chemotherapy (70). Regimens of choice are: four cycles of PEI/VIP or four cycles of VeIP. At present it is impossible to determine whether conventionally dosed cisplatin based combination chemotherapy is sufficient as first salvage treatment or whether early intensification of first-salvage treatment with high-dose chemotherapy should be attempted (71). Therefore treatment of these rare patients within clinical trials and at experienced centres is of outmost importance.

8.3.2 Non-seminoma

Standard salvage treatment after first-line chemotherapy consists of either four cycles of PEI/VIP or four cycles of VeIP, respectively (Table 6). Conventionally dosed salvage chemotherapy may achieve long-term remissions in 15 to 40% of patients, depending on individual risk factors (72,73). Prognostic indicators of response to salvage therapy are: location and histology of the primary tumor, response to first line treatment, duration of remissions and level of AFP and β -hCG at relapse (72-75). Salvage therapy with VeIP is probably not superior

to other conventionally dosed cisplatin based combination regimens (71,73,74). The use of conventionally dosed combination regimens with more than three agents will increase toxicity without improving treatment outcome (76). Depending on the presence of adverse prognostic factors, the results of salvage therapy after first-line cisplatin based treatment are unsatisfactory (72,77). Although some Phase II trials indicate a 10% improvement in survival with early intensification of first salvage treatment using high-dose chemotherapy, others fail to demonstrate such improvement (78-80). Recently, Taxol and Gemcitabine have proved to be active in the treatment of refractory germ cell tumours; both drugs are synergistic with Cisplatin (81-83). However, all of these patients should be entered into ongoing multicentre studies to define the optimal approach to salvage treatment and should be referred to centers experienced in caring for relapse and/or refractory patients (71).

Table 6: Standard VIP (VeIP)

Drug	VIP (VeIP)
Cisplatin	20 mg/m ² days 1–5 ^a
Etoposide (vinblastine)	75 mg/m ² , days 1–5 (0.11 mg/kg, days 1, 2)
Ifosfamide	1.2 g/m ² , days 1–5

VIP = VP-16 (vinblastine) ifosfamide and cisplatin; VeIP = velban, ifosfamide and cisplatin;

^a Plus hydration.

8.4 Salvage surgery

Residual tumors after salvage chemotherapy should be resected within four to six weeks after marker normalisation or when a marker plateau is reached. In case of marker progression after salvage treatment and lack of other chemotherapeutic options, resection of residual tumors ('desperation surgery') should be considered if complete resection of all tumor seems feasible (about 25% long-term survival may be achieved) (47,55,72,85-95).

8.5 Treatment of brain metastases

Brain metastases occur in the frame of a systemic relapse and rarely as an isolated relapse. The long-term survival of patients presenting with brain metastasis at initial diagnostic is poor (30-40%), but even poorer is the development of a brain metastases as a recurrent disease (five years survival 2-5%) (96,97). Chemotherapy is the initial treatment in this case and some data support the use of consolidation radiotherapy even in case of a total response after chemotherapy (98). Surgery can be considered in case of a persistent solitary metastasis depending on the systemic state, the histology of the primary tumor and the location of the metastasis.

8.6 GUIDELINES FOR THE TREATMENT OF METASTATIC GERM CELL TUMOURS

1. Low volume NSGCT stage II can be treated either by RPLND (plus surveillance or two cycles of chemotherapy) or by primary chemotherapy (GRADE A recommendation)
2. In metastatic NSGCT with a good prognosis, three courses of BEP is the primary treatment of choice (GRADE A recommendation)
3. In metastatic NSGCT with an intermediate or poor prognosis, the primary treatment of choice is four courses of standard BEP (GRADE A recommendation)
4. Surgical resection of residual masses after chemotherapy in NSGCT is indicated in case of a residual mass > 1cm and when serum levels of tumour markers are normal or normalizing (GRADE B recommendation)
5. Metastatic seminoma with less than N3M1 disease can be treated initially with radiotherapy. When necessary, chemotherapy can be used as a salvage treatment with the same schedule as for the corresponding prognostic groups of NSGCT (GRADE A recommendation)
6. Advanced seminoma (N3 or M1) should be treated with primary chemotherapy according to the same principles used for NSGCT (GRADE A recommendation).

8.7 REFERENCES (Treatment Metastatic disease)

1. International Germ Cell Collaborative Group.

International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603. EBM Ia,IIa, IIb, III.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9053482&dopt=Abstract

2. **Frohlich MW, Small EJ.**
Stage II nonseminomatous testis cancer: the roles of primary and adjuvant chemotherapy.
Urol Clin North Am 1998;25:451-459.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9728214&dopt=Abstract
3. **Baniel J, Donohue JP.**
Cost and risk benefit considerations in low stage (I and II) nonseminomatous testicular tumors.
AUA Update Series 1997;26:50-55.
4. **Weissbach L, Bussar-Maatz R, Fletcher H, Pichlmeier U, Hartmann M, Keller L.**
RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors.
Results of a prospective multicenter trial including quality of life assessment. Eur Urol 2000;37:582-594.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10765098&dopt=Abstract
5. **Saxman S, Finch D, Gonin R, Einhorn LH.**
Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide and cisplatin in favorable-prognosis germ-cell tumors: the Indiana University Experience.
J Clin Oncol 1998;16:702-06. EBM Ib.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9469360&dopt=Abstract
6. **de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, Rea LA, Collette L, Sylvester R.**
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997;15:1837-1843. EBM Ib.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9164193&dopt=Abstract
7. **Shelley MD, Burgon K, Mason MD.**
Treatment of testicular germ-cell cancer: a Cochrane evidence-based systematic review.
Cancer treatment reviews, 2002;28:237-253. EBM Ia.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12435371&dopt=Abstract
8. **Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP.**
Randomized trial of bleomycin, etoposide and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer trial.
J Clin Oncol 1997;15:1844-1852. EBM Ib.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9164194&dopt=Abstract
9. **Bokemeyer C, Kuczyk MA, Köhne H, Einsele H, Kynast B, Schmoll HJ.**
Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose intensive chemotherapy. Ann Hematol 1996;72:1-9. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8605273&dopt=Abstract
10. **De Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fossa SD, Cook P, de Pryck L, Stenning S, Collette L.**
Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5- day schedule in good-prognosis Germ Cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical research Council. J Clin Oncol 2001;19:1629-1640. EBM Ib.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11250991&dopt=Abstract
11. **Xiao H, Mazumdar M, Bajorin DF, Sarosdy M, Vlamis V, Spicer J, Ferrara J, Bosl GJ, Motzer RJ.**
Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin.
J Clin Oncol 1997;15:2553-2558. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9215824&dopt=Abstract

12. **Fossa SD, Kaye SB, Mead GM, Cullen M, de Wit R, Bodrogi I, van Groenigen CJ, de Mulder PH, Stenning S, Lallemand E, de Pryck L, Collette L.**
Filgastrim during combination chemotherapy of patients with poor prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party. J Clin Oncol 1998;16:716-724. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9469362&dopt=Abstract
13. **De Wit R, Stoter G, Sleijfer DT, Neijt JP, ten Bokkel Huinink WW, de Pryck L, Collette L, Sylvester R.**
Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998;78:828-832. EBM Ib.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9743309&dopt=Abstract
14. **De Witt R, Louwerens M, de Mulder PH, Verweij J, Rodenhuis S, Schornagel J.**
Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP. Int J Cancer 1999;83:831-833. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10597204&dopt=Abstract
15. **Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ.**
Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: and Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukaemia Group B Study. J Clin Oncol 1998;16:1287-1293. EBM Ib.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9552027&dopt=Abstract
16. **Sonneveld D, Hoekstra HJ, Van der Graaf WTA, Sluiter WJ, Mulder NH, Willemse PH, Koops HS, Sleijfer DT.**
Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification system during the cisplatin era. Cancer 2001;91: 1304-1315. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11283931&dopt=Abstract
17. **Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V.**
High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997; 15:2546-2552. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9215823&dopt=Abstract
18. **Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C.**
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol 1999;17:3450-3456. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10550141&dopt=Abstract
19. **Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V.**
High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997; 15:2546-2552. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9215823&dopt=Abstract
20. **Gerl A, Clemm C, Lamerz R, Mann K, Wilmanns W.**
Prognostic implications of tumor marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease. Eur J Cancer 1993;29 A:961-965. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7684597&dopt=Abstract

21. **Murphy BA, Motzer RJ, Mazumdar M, Vlamis V, Nisselbaum J, Bajorin D, Bosl GJ.**
Serum tumor markers decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. *Cancer* 1994;73:2520-2526. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7513603&dopt=Abstract
22. **Andre F, Fizazi K, Culine S, Droz J, Taupin P, Lhomme C, Terrier-Lacombe M, Theodore C.**
The growing teratoma syndrome : results of therapy and long-term follow-up of 33 patients. *Eur J Cancer* 2000;36:1389-1394. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10899652&dopt=Abstract
23. **De Wit R, Collette L, Sylvester R, de Mulder PH, Sleyfer DT, ten Bokkel Huinink WW, Kaye SB, van Oosterom AT, Boven E, Stoter G.**
Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. *Br J Cancer* 1998;78:1350-1355. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9823978&dopt=Abstract
24. **Zon RT, Nichols C, Einhorn LH.**
Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. *J Clin Oncol* 1998;16:1294-1297. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9552028&dopt=Abstract
25. **Fossa AD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJ, Cook PA.**
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. *Br J Cancer*, 1999;80:1392-1399. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10424741&dopt=Abstract
26. **Fossa SD, Borge L, Aass N, Johannessen NB, Stenwig AE, Kaalhus O.**
The treatment of advanced metastatic seminoma: experience in 55 cases. *J Clin Oncol* 1987;5:1071-1077. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2439660&dopt=Abstract
27. **Herr HW, Bosl G.**
Residual mass after chemotherapy for seminoma: changing concepts of management. *J Urol* 1987;137:1234-1235. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2438431&dopt=Abstract
28. **Hofmockel G, Gruss A, Theiss M.**
Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. *Urol Int* 1996;57:38-42. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8840489&dopt=Abstract
29. **Kamat MR, Kulkarni JN, Tongoankar HB, Ravi R.**
Value of retroperitoneal lymph node dissection in advanced testicular seminoma. *J Surg Oncol* 1992;51:65-67. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1381455&dopt=Abstract
30. **Loehrer PJ Sr, Birch R, Williams SD, Greco FA, Einhorn LH.**
Chemotherapy of metastatic seminoma: the SouthEastern Cancer Study Group Experience. *J Clin Oncol* 1997;15:1212-1220. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2442317&dopt=Abstract
31. **Motzer R, Bosl G, Heelan R, Fair W, Whitmore W, Sogani P, Herr H, Morse M.**
Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. *J Clin Oncol* 1987;5:1064-1070. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3598610&dopt=Abstract

32. **Peckham MJ, Horwich A, Hendry WF.**
Advanced seminoma treatment with cisplatin based combination chemotherapy or carboplatin (JM8). Br J Cancer 1985;52:7-13. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3893507&dopt=Abstract
33. **Duchesne GM, Stenning SP, Aass N, Mead GM, Fossa SD, Oliver RT, Horwich A, Read G, Roberts IT, Rustin G, Cullen MH, Kaye SB, Harland SJ, Cook PA.**
Radiotherapy after Chemotherapy for metastatic seminoma -a diminishing role. Eur J Cancer 1997; 33: 829-835. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9291801&dopt=Abstract
34. **Bamberg M, Classen J.**
Stellenwert der Strahlentherapie von residuatumoren nach Chemotherapie metastasierter Seminome. Strahlenther Onkol 1998;174: 442-443.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9739390&dopt=Abstract
35. **Puc H, Heelan R, Mazumdar M, Herr H, Scheinfeld J, Vlamis V, Bajorin DF, Bosl GJ, Mencil P, Motzer RJ.**
Management of residual mass in advanced seminoma: results and recommendations from Memorial Sloan Kettering Cancer Center. J Clin Oncol 1996;14:454-460. EBM IV.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8636757&dopt=Abstract
36. **Herr HW, Scheinfeld J, Puc HS, Heelan R, Bajorin DF, Mencil P, Bosl GJ, Motzer RJ.**
Surgery for a post-chemotherapy residual mass in seminoma. J Urol 1997;157 860-862. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9072586&dopt=Abstract
37. **Mosharafa AA, Foster RS, Leibovich BC, Bihrl R, Donahue JP.**
Is the post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 2002;167:172 abstract 692. EBM III.
38. **Kuczyk M, Machtens S, Stief C, Jonas U.**
Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (GCT). Int J Cancer 1999; 83:852-855. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10597210&dopt=Abstract
39. **Fossa SD, Ous S, Lien HH, Stenwig AE.**
Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 1989;141:557-559. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2918591&dopt=Abstract
40. **Toner GC, Panicek DM, Heelan RT, Geller NL, Lin SY, Bajorin D, Motzer RJ, Scher HI, Herr HW, Morse MJ, et al.**
Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990;8:1683-1694. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2170590&dopt=Abstract
41. **Donohue JP, Rowland RG, Kopecky K, Steidle CP, Geier G, Ney KG, Einhorn L, Williams S, Loehrer P.**
Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 1987;137:1176-1179. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3035236&dopt=Abstract
42. **Richie JP.**
The surgical management of advanced abdominal disease. Semin Urol 1984;2:238-243.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6505446&dopt=Abstract

43. **Stomper PC, Fung CY, Socinski MA, Jochelson MS, Garnick MB, Richie JP.**
 Detection of retroperitoneal metastases in early-stage nonseminomatous testicular cancer: analysis of different CT criteria. *Am J Roentgenol* 1987;149:1187-1190. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2825494&dopt=Abstract
44. **Aprikian AG, Herr HW, Bajorin DF, Bosl GJ.**
 Resection of post-chemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. *Cancer* 1994;74:1329-1334. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8055456&dopt=Abstract
45. **Herr HW.**
 Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? *Br J Urol* 1997;80:653-657. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9352708&dopt=Abstract
46. **Hendry WF, A'Hern RP, Hetherington JW, Peckham MJ, Dearnaley DP, Horwich A.**
 Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumors: prognostic value and therapeutic benefit. *Br J Urol* 1993;71:208-213.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8384914&dopt=Abstract
47. **Wood DP, Herr HW, Heller G, Vlamis V, Sogani PC, Motzer RJ, Fair WR, Bosl GJ.**
 Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. *J Urol* 1992;148:1812-1815. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1331547&dopt=Abstract
48. **Baniel J, Foster RS, Rowland RG, Bihle R, Donohue JP.**
 Complications of post-chemotherapy retroperitoneal lymph node dissection. *J Urol* 1995;153:976-980. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7853586&dopt=Abstract
49. **Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C.**
 Post-chemotherapy resection of residual masses from metastatic non-seminomatous germ cell tumors. *Ann Oncol* 1997;8:531-538. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9261521&dopt=Abstract
50. **Rabbani F, Goldenberg SL, Gleave ME, Paterson RF, Murray N, Sullivan LD.**
 Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of the residual mass sufficient?. *Br J Urol* 1998;81:295-300. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9488075&dopt=Abstract
51. **Tekgul S, Özen HA, Celebi I, Ozgu I, Ergen A, Demircin M, Remzi D.**
 Postchemotherapeutic surgery for metastatic testicular germ cell tumors: results of extended primary chemotherapy and limited surgery. *Urology* 1994;43:349-354. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8134989&dopt=Abstract
52. **Steyerberg EW, Keizer HJ, Fossa SD, Sleijfer DT, Toner GC, Schraffordt Koops H, Mulders PF, Messemer JE, Ney K, Donohue JP, et al.**
 Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. *J Clin Oncol* 1995;13:1177-1187. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7537801&dopt=Abstract
53. **Hartmann JT, Candelaria M, Kuczyk MA, Schmoll HJ, Bokemeyer C.**
 Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. *Eur J Cancer* 1997;33:843-847. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9291803&dopt=Abstract

54. **Stenning SP, Parkinson MC, Fisher C, Mead GN, Cook PA, Fossa SD, Horwich A, Jones WG, Newlands ES, Oliver RT, Stenwig AE, Wilkinson PM.**
Post-chemotherapy residual masses in germ cell tumor patients: content, clinical features and prognosis. Medical Research Council Testicular Tumour Working Party. *Cancer* 1998;83:1409-1419. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9762943&dopt=Abstract
55. **Weinknecht S, Hartmann M, Weissbach L.**
Bei welchen markerpositiven Patienten mit Keimzelltumoren ist die Residualtumoresektion sinnvoll? *Urologe A* 1998;37:621-624. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9887490&dopt=Abstract
56. **Hendry WF, Norman AR, Dearnaley DP, Fisher C, Nicholls J, Huddart RA, Horwich A.**
Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. *Cancer* 2002;94:1668-1676. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11920527&dopt=Abstract
57. **Sheinfeld J,**
The role of adjunctive post-chemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. *Sem Urol Oncol* 2002;20:262-271. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12489059&dopt=Abstract
58. **Foster RS, Donohue JP.**
Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy? *Urol Clin North Am* 1998;25:479-484. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9728217&dopt=Abstract
59. **Steyerberg EW, Kaiser HJ, Habbema JD.**
Prediction models of the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group. *Int J Cancer* 1999;83:856-859. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10597211&dopt=Abstract
60. **Vergouwe Y, Steyerberg EW, De Wit R, Roberts JT, Keizer HJ, Collette L, Stenning SP, Habbema JD.**
External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients. *Br J Cancer* 2003;88:843-847. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12644820&dopt=Abstract
61. **Fizazi K, Tjulandin S, Salvioni R, Germa-Lluch JR, Bouzy J, Ragan D, Bokemeyer C, Gerl A, Flechon A, de Bono JS, Stenning S, Horwich A, Pont J, Albers P, De Giorgi U, Bower M, Bulanov A, Pizzocaro G, Aparicio J, Nichols CR, Theodore C, Hartmann JT, Schmoll HJ, Kaye SB, Culine S, Droz JP, Mahe C.**
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy—results from an international study group. *J Clin Oncol* 2001;19:2647-2657. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11352956&dopt=Abstract
62. **Einhorn LH, Williams SD, Mandelbaum I, Donohue JP.**
Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. *Cancer* 1981;48: 904-908. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6168361&dopt=Abstract
63. **Fox EP, Weathers TS, Williams SD, Loehrer PJ, Ulbright TM, Donohue JP, Einhorn LH.**
Outcome analysis for patients with persistent nonteratoma germ cell tumor in postchemotherapy retroperitoneal lymph node dissection. *J Clin Oncol* 1993;11:1294-1299. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8391067&dopt=Abstract
64. **Gerl A, Clemm C, Schmeller N, Dienemann H, Lamerz R, Kriegmair M, Wilmanns W.**
Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumors. *Ann Oncol* 1995;6:483-488. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7545430&dopt=Abstract

65. **Hollender A, Stenwig EA, Ous S, Fossa SD.**
Survival of patients with viable malignant non-seminomatous germ cell tumor persistent after cisplatin-based induction chemotherapy. *Eur Urol* 1997;31:141-147. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9076455&dopt=Abstract
66. **Bajorin DF, Herr H, Motzer RJ, Bosl G.**
Current perspectives on the role of adjuvant surgery in combined modality treatment for patients with germ cell tumors. *Semin Oncol* 1992;19:148-158.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1372757&dopt=Abstract
67. **Pizzocaro G, Nicolai N, Milani A.**
Is further chemotherapy necessary in radically resected residual cancer in non-seminomatous germ cell tumors (NSGCT) of the testis following induction chemotherapy? *Proc ASCO* 1998;17: 309a (abstract 1191).
68. **Fizazi K, Tjulandin S, Salvioni R, Germa-Lluch JR, Bouzy J, Ragan D, Bokemeyer C, Gerl A, Flechon A, de Bono JS, Stenning S, Horwich A, Pont J, Albers P, De Giorgi U, Bower M, Bulanov A, Pizzocaro G, Aparicio J, Nichols CR, Theodore C, Hartmann JT, Schmoll HJ, Kaye SB, Culine S, Droz JP, Mahe C.**
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy- results from an international study group. *J Clin Oncol* 2001 19:2647-2657. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11352956&dopt=Abstract
69. **Debono DJ, Heilman DK, Einhorn LH, Donohue JP.**
Decision analysis for avoiding post-chemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. *J Clin Oncol* 1997;15:1455-1464. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9193340&dopt=Abstract
70. **Miller KD, Loehrer PJ, Gonin R, Einhorn LH.**
Salvage chemotherapy with vinblastine, ifosfamide and cisplatin in recurrent seminoma. *J Clin Oncol* 1997;15:1427-1431. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9193335&dopt=Abstract
71. **Beyer J, Bokemeyer C, Schmoll HJ.**
Salvagerapathie rezidivierter und refraktärer Hodentumoren. *Onkologe* 1998; 4: 541-546.
72. **Fossa SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJ, Cook PA.**
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. *Br J Cancer* 1999;80:1392-1399. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10424741&dopt=Abstract
73. **Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH.**
Vinblastine plus ifosfamide plus cisplatin as initial salvagerapathie in recurrent germ cell tumor. *J Clin Oncol* 1998;16:2500-2504. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9667270&dopt=Abstract
74. **Beyer J, Rick O, Siegert W, Bokemeyer C.**
Salvage chemotherapy in relapsed germ cell tumors. *World J Urol* 2001;19:90-93. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11374323&dopt=Abstract
75. **Schmoll HJ, Beyer J.**
Prognostic factors in metastatic germ cell tumors. *Semin Oncol* 1998;25:174-185. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9562450&dopt=Abstract

76. **Kaye SB, Mead GM, Fossa SD, Cullen M, de Wit R, Bodrogi I, vanGroeningen C, Sylvester R, Collette L, Stenning S, de Pryck L, Lallemand E, de Mulder P.**
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. *J Clin Oncol* 1998; 16:692-701. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9469359&dopt=Abstract
77. **Beyer J, Schmoll HJ.**
Prognosefaktoren bei metastasierten seminomatösen und nichtseminomatösen Hodentumoren. *Onkologie* 1998; 4: 518-523.
78. **Beyer J, Stenning S, Gerl A, Fossa S, Siegert W.**
High-dose versus conventional-dose chemotherapy as a first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched pair analysis. *Ann Oncol* 2002;13:599-605. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12056711&dopt=Abstract
79. **Bhatia S, Abonour R, Porcu P, Seshadri R, Nichols CR, Cornetta K, Einhorn LH.**
High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. *J Clin Oncol* 2000;18:3346-3351. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11013274&dopt=Abstract
80. **Rosti G, Pico JL, Wandt H et al.**
High-dose chemotherapy (HDC) in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors (GCT): first results of a prospective randomised trial of the European Group for Blood and Marrow Transplantation (EBMT): IT-94 study. *Proc Ann Soc Clin Oncol*, 2002; 21: 180a, abstract 716. EBM Ib.
81. **Reinhorn LH, Rajhavan D, Kindlen H.**
A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory advanced germ cell tumors. *Proc. ASCO* 1999; 18: 207 A (abstract 796). EBM IIa.
82. **Motzer JR, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, Bajorin D, Bosl GJ.**
Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. *J Clin Oncol* 2000;18:2413- 2418. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10856101&dopt=Abstract
83. **Bokemeyer C, Gerl A, Schoffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ, Kanz L.**
Gemcitabine in patients with relapse or cisplatin refractory testicular cancer. *J Clin Oncol* 1999;17:512-516. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10080593&dopt=Abstract
84. **Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH.**
Late relapse of testicular cancer. *J Clin Oncol* 1995;13:1170-1176. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7537800&dopt=Abstract
85. **Tiffany P, Morse MJ, Bosl G, Vaughan ED Jr, Sogani PC, Herr HW, Whitmore WF jr.**
Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors. *Cancer* 1986;57:978-983. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3002596&dopt=Abstract
86. **Cassidy J, Lewis CR, Kaye SB, Kirk D.**
The changing role of surgery in metastatic non-seminomatous germ cell tumour. *Br J Cancer* 1992;65:127-129.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1370759&dopt=Abstract
87. **Coogan CL, Foster RS, Rowland RG, Bihrlé R, Smith ER jr., Einhorn LH, Roth BJ, Donohue JP.**
Post-chemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. *Urology* 1997;50:957-962. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9426730&dopt=Abstract

88. **Eastham JA, Wilson TG, Russell C, Ahlering TE, Skinner DG.**
Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. *Urology* 1994;43:74-80. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7506856&dopt=Abstract
89. **Foster RS, Donohue JP.**
Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy?
Urol Clin North Am 1998;25:479-484.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9728217&dopt=Abstract
90. **Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W.**
Late relapse of germ cell tumors after cisplatin-based chemotherapy. *Ann Oncol* 1997;8:41-47. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9093706&dopt=Abstract
91. **Kisbenedek L, Bodrogi I, Szeldeli P, Baki M, Tenke P, Horti J.**
Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumors remaining marker positive after inductive chemotherapy. *Int Urol Nephrol* 1995;27:325-329. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7591598&dopt=Abstract
92. **Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ, Einhorn LH.**
Surgical salvage of chemorefractory germ cell tumors. *J Clin Oncol* 1993;11:324-329. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8381163&dopt=Abstract
93. **Nichols C.**
Treatment of recurrent germ cell tumors. *Semin Surg Oncol* 1999;17:268-274.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10588856&dopt=Abstract
94. **Ravi R, Ong J, Oliver RT, Badenoch DF, Fowler CG, Hendry WF.**
Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumors. *Br J Urol* 1998; 81:884-888. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9666776&dopt=Abstract
95. **Albers P, Ganz A, Hanning E, Miersch WD, Muller SC.**
Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. *J Urol*, 2000;164:381-384. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10893590&dopt=Abstract
96. **Fossa SD, Bokemeyer C, Gerl A, Culine S, Jones WG, Mead GM, Germa-Luch JR, Pont J, Schmoll HJ, Tjulandin S.**
Treatment outcome of patients with brain metastases from malignant germ cell tumors. *Cancer*, 1999;85:988-997. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10091779&dopt=Abstract
97. **Bokemeyer C, Nowak P, Haupt A, et al.**
Treatment of brain metastases in patients with testicular cancer. *J Clin Oncol*, 1997; 15:1449-1454. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9193339&dopt=Abstract
98. **Hartmann JT, Bamberg M, Albers P et al.**
Multidisciplinary treatment and prognosis of patients with central nervous metastases (CNS) from testicular germ cell tumor (GCT) origin. *Proc Ann Soc Clin Oncol*, 2003; 22:400 abstract 1607. EBM III.

9 FOLLOW-UP AFTER CURATIVE THERAPY

9.1 General considerations

In spite of the fact that relative information exists on the value of follow-up testing of asymptomatic patients after potentially curative therapy, testis cancer, the most curable human tumor is an excellent model for post curative therapy surveillance.

The selection of the test to be performed in follow-up should adhere to the following principles (1):

- A *The interval between examinations and duration of testing should be consistent with the time of maximal risk of recurrence and the natural history of the tumor*
- B *The tests should be directed at the most likely sites of recurrence and should have a high predictive value, both positive and negative*
- C *Therapy should be available that will result in cure of the recurrence, significant prolongation of life or palliation symptoms. The initiation of earlier therapy should improve the outcome compared with therapy given when the patient becomes symptomatic from the tumor recurrence.*
- D *The increased risk of second malignancy, both in the primary site and in other tissues that may have been exposed to the same carcinogens or in which there is epidemiologic evidence of increased risk, should also guide the ordering tests. Malignant and non malignant complications of therapy must also be considered. Such testing should also be performed with a frequency and duration consistent with the nature of the risk and include only tests with high positive and negative predictive values*

The following considerations apply in a general manner for the selection of an appropriate schedule and testing in the follow-up of all stages of Testis Tumor:

- Most recurrences after curative therapy will occur in the first two years; consequently surveillance should be most frequent and intensive during this time.
- Late relapses can occur beyond 5 years therefore yearly follow-up for life may be advocated.
- After RPLND relapse in the retroperitoneum is rare, the most likely site of recurrence being the chest.
- The value of chest X-ray has been recently questioned in the follow-up of patients with disseminated disease after complete remission (2).
- CT of the chest has a higher predictive value than chest X-ray (3)
- The results of therapy are dependant on the bulk of disease, thus an intensive strategy to detect presymptomatic disease may be justifiable.
- After chemotherapy or radiotherapy a small long-term risk for secondary malignancies development exists.

In testis tumor the aims of follow-up are:

- to detect relapse as early as possible in all stages,
- to detect an asynchronous contralateral carcinoma of the testis in an early phase,
- to avoid unnecessary treatment in Stage I.

Because different treatment policies are available for Stage I and low-volume of metastatic disease (resulting in the same survival but different recurrence rate), in those stages the intensity of the follow-up should be determined by the rate and timing of relapse. The site of relapse for each one of the policies should dictate the tests to be performed during the follow-up.

Whether in early or advanced stages the tests to be performed during follow-up are:

- Physical examination (search for neck and abdominal masses, gynaecomastia, examination of groins, superficial nodes and the remaining testis),
- Serum Tumour Markers determination (AFP, beta-hCG and LDH),
- Chest X-ray and or Chest CT, Abdominal and pelvic CT or abdominal ultrasound,
- and Brain CT in case of neurological symptoms, and Bone scan in case of bone pain.

Currently, not enough evidence is available in the literature from which to derive strict recommendations on timing and testing during follow-up. *The nature of the recommendations on follow-up is of grade B or C with a consistent lack of randomized studies. Therefore, the authors want to emphasize that the following recommendations represent the minimum standard of follow-up. Any other tests (e.g., hormonal determinations, spermograms, neurological examinations) or more frequent schedules of evaluation may be performed on the basis of a clinical protocol or with investigative purposes.*

9.2 REFERENCES (General considerations on follow-up of Testis Tumor)

1. Edelman MJ, Meyers FJ, Siegel D.

The utility of Follow-up testing after curative cancer therapy. *JGIM* 1997;12:318-331.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9159703&dopt=Abstract

2. Rathmell AJ, Brand IR, Carey BM, Jones WG.

Early detection of relapse after treatment for metastatic germ cell tumour of the testis: an exercise in medical audit. *Clin Oncol (R Coll Radiol)* 1993;5:34-38. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7678749&dopt=Abstract

3. Gietema JA, Meinardi MT, Sleifer DT, Hoekstra HJ, van der Graaf WT.

Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. *Ann Oncol* 2002;13:1616-1620. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12377651&dopt=Abstract

9.3 Follow-up stage I non-seminoma

Approximately 5% of patients with clinical stage I NSGCT present with elevated levels of tumour markers after orchiectomy and up to 25-30% relapse during the first 2 years (1-9).

The follow-up schedule will differ depending on which of the three possible treatment strategies was chosen: surveillance, nerve-sparing retroperitoneal lymphadenectomy (RLND) or primary chemotherapy.

9.3.1 Follow-up after surveillance

The results of a surveillance policy depend upon a careful pre-operative staging procedure and follow-up management. Half of the relapses will occur in the first 6 months; however, recurrent disease has been detected as late as 6 years after orchiectomy. In a 'wait and see' policy, relapses will occur in 30% of cases. Of these relapses, 80% will occur in the first 12 months after orchiectomy and approximately 12% during the second year. The median time to relapse is 6 months (range 1-62 months), but relapses after 3-5 years, and even later, may still occur, with an annual rate of 4% (10-11). Relapse occurs mainly in the retroperitoneum; approximately 20% of patients have evident metastases in the retroperitoneum and 10% in the mediastinum and lungs (12). Sometimes the only indication is an elevated level of tumor markers.

Careful observation during the first 6-12 months after orchiectomy is mandatory; thereafter, the interval may be longer. Surveillance should continue for a minimum of 6 years and indefinite yearly follow-up is advocated by some. There is no universally accepted protocol for surveillance. A recommended follow-up schedule is shown in Table 7. It is particularly difficult to establish recommendations for those patients with negative pre-operative tumour markers levels.

Table 7: Recommended follow-up schedule in a surveillance policy: – stage I non-seminoma

Procedure	Year			
	1	2	3-5	6-10
Physical examination	Monthly	4- 6 times	Twice/year	Once/year
Tumour markers	9-12 times (Monthly the first 6 months)	4-6 times	Twice/year	Once/year
Chest X-ray	9-12 times (Monthly for the first 6 months)	4-6 times	Twice/year	Once/year
Abdominal CT scan	3-4 times	Twice	Once/year	If indicated

9.3.2 Follow-up after nerve-sparing RLND

Retroperitoneal relapse after a properly performed nerve-sparing RLND is extremely rare. RLND should eliminate the retroperitoneal nodes as a site of relapse, and thus the need for repeated abdominal CT scans. The USA Intergroup data show retroperitoneal relapse in 7/264 patients with pathological stage I disease (and 20 pulmonary relapses); four of these seven had no marker elevation (13). In the Indiana series, only one relapse in 559 cases was reported (14). If a relapse occurs, it is generally in the chest, neck or at the margins of the surgical field. Pulmonary relapses occur in 10-12% of patients and more than 90% of those relapses occur within 2 years of RLND (15,16). The recommended follow-up schedule is shown in Table 8.

Table 8: Recommended follow-up schedule after retroperitoneal lymphadenectomy or adjuvant chemotherapy - stage I non-seminoma

Procedure	Year			
	1	2	3-5	5-10
Physical examination	6 times	3 times	2 per year	Once/year ^a
Tumour markers	6 times	3 times	2 per year	Once/year ^a
Chest X-ray	6 times	3 times	2 per year	Once/year ^a
Abdominal computed tomography scan	Twice	Once	If indicated ^b	If indicated
Abdominal ultrasound	Twice ^c	Twice ^c	Twice/year	Once/year

^a Grade C recommendation

^b Due to a risk of late, slow-growing teratoma in the retroperitoneum after adjuvant chemotherapy once a year.

^c Alternating with abdominal CT scan.

9.3.3 Follow-up after adjuvant chemotherapy

Although the number of patients treated using adjuvant chemotherapy is still small, some prospective reports with long-term follow-up show a very low relapse rate (1-3,17) of about 3%. The need for repeated and long-term assessment of the retroperitoneum is still not clear. Primary chemotherapy in the treatment of NSGCT cannot be regarded as investigational, but still has to be offered in the setting of clinical trials. The follow-up schedule will depend on the results of these studies, but will probably be similar to that recommended for RPLND (Table 8). Owing to the risk of developing a late, slow-growing teratoma in the retroperitoneum after adjuvant chemotherapy, an abdominal CT or an ultrasound examination should also be performed (at least) annually during the third to fifth year.

9.4 REFERENCES (Follow-up stage I non-seminoma)

- Cullen MH, Stenning SP, Parkinson MC, Fossa SD, Kaye SB, Horwich AH, Harland SJ, Williams MV, Jakes R.**
Short-course adjuvant chemotherapy in high risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council Report. J Clin Oncol 1996;14:1106-1113.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8648364&dopt=Abstract&itool=iconabstr
- Pont J, Albrecht W, Postner G, Sellner F, Angel K, Holtl W. EBM III.**
Adjuvant chemotherapy for high risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996;14:441-448. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8636755&dopt=Abstract&itool=iconabstr
- Bohlen D, Borner M, Sonntag RW, Fey MF, Studer UE.**
Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 1999;161:1148-1152. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10081858&dopt=Abstract&itool=iconabstr
- Lashley DB, Lowe BA.**
A rational approach to managing stage I nonseminomatous germ cell cancer. Urol Clin North Am 1998;25:405-423.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9728211&dopt=Abstract
- Bosl GJ, Motzel RJ.**
Testicular germ-cell cancer. N Engl J Med 1997; 337: 242-253.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9227931&dopt=Abstract
- Tjan-Heijnen VCG, Oosterhof GON, de Wit R, de Mulder PHM.**
Treatment of germ cell tumours: state of the art. Eur J Surg Oncol 1997;23:110-117.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9158183&dopt=Abstract

7. **Baniel J, Donahue JP.**
Cost and risk benefit considerations in low stage (I and II) non seminomatous testicular tumor. AUA Update Series 1997;16 (lesson 7):49-56.
8. **Lowe BA.**
Surveillance versus nerve-sparing retroperitoneal lymphadenectomy in stage I germ cell tumors. Urol Clin North Am 1993;20:75-83. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8381999&dopt=Abstract
9. **Sternberg CN.**
Role of primary chemotherapy in stage I and low-volume stage II nonseminomatous germ-cell testis tumors. Urol Clin North Am 1993;20:93-109. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8382000&dopt=Abstract
10. **Read G, Stening SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, Cook PA.**
Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992;10:1762-1768. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1403057&dopt=Abstract
11. **Colls BM, Harvey VJ, Skelton L, Frampton CM, Thompson PI, Bennett M, Perez DJ, Dady PJ, Forgeson GV, Kennedy IC.**
Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumors: 17 years' experience in a national study in New Zealand. Br J Urol Int 1999;83:76-82. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10233456&dopt=Abstract
12. **Gels ME, Hoekstra HJ, Sleijfer DT, Marrink J, de Bruijn HW, Molenaar WM, Freling NJ, Droste JH, Schraffordt Koops H.**
Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 1995;13:1188-1194. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7537802&dopt=Abstract
13. **McLeod DG, Weiss RB, Stablein DM, Muggia FM, Paulson DF, Ellis JH, Spaulding JT, Donohue JP.**
Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol 1991;145:1178-1183. EBM IIa.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1851890&dopt=Abstract
14. **Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihle R.**
Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer: review of the Indiana University Experience 1965-1989. Br J Urol 1993;71:326-335. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8386580&dopt=Abstract
15. **Schmoll HJ, Weissbach L.**
Diagnostik und Therapie von Hodentumoren, Interdisziplinäre Konsensus-Konferenz, Halle (Saale), 1996. EBM IIa-IIb-III.
16. **Klepp O, Flodgren P, Maartman-Moe H, Lindholm CE, Unsgaard B, Teigum H, Fossa SD, Paus E.**
Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatoustestis cancer. Value of pre-and post-orchietomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer project (SWENOTECA). Ann Oncol 1990;1:281-288. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1702312&dopt=Abstract
17. **Oliver RTD, Raja M-A, Ong J, Gallagher CJ.**
Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage I malignant teratoma on overall relapse rate of stage I cancer patients. J Urol 1992;148:1453-1456. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1279211&dopt=Abstract

9.5 Follow-up stage I seminoma

The majority of patients with seminoma (70-80%) present with clinical stage I disease at diagnosis (1). In 15-20% of cases, there is nodal radiological involvement at the level of the retroperitoneum and only 5% of patients present with distant metastasis (1).

The relapse rate varies between 1% and 20%, depending on the post-orchietomy therapy chosen.

Only up to 30% of seminomas present with elevation of beta-hCG at diagnosis or in the course of the disease. Consequently, in most cases, measurement of blood markers will not be a reliable test for follow-up (2).

The treatment options post-orchietomy in stage I seminoma are retroperitoneal radiotherapy, surveillance and adjuvant chemotherapy. Due to extreme radio and chemosensitivity, high cure rates of almost 100% are reached with each of the approaches, even in case of relapse. The costs of the different therapies vary, as do the expected side-effects (3-5).

The optimal schedule of follow-up has yet to be defined and will differ according to the treatment chosen. Different tests have to be performed according to the relapse time and pattern of relapse.

9.5.1 Follow-up after radiotherapy

Low doses of radiotherapy (20-24 Gy) limited to the retroperitoneal or the hockey stick field achieve an overall survival rate of approximately 99% at 5-10 years (6-10). The rate of relapse is 1- 2% and the most common time of presentation is within 18 months after treatment (4,7,11-13), although late relapses have also been described (14). The site of relapse is mainly at the supradiaphragmatic lymph nodes, mediastinum, lungs or bones. In a small proportion of cases, the tumour will relapse in the inguinal or external iliac nodes (1). The side-effects of radiotherapy include impaired spermatogenesis, gastrointestinal symptoms (peptic ulceration) and induction of second malignancies (4,15,16). Up to 50% of patients can develop moderate toxicity Grade I-II (6). The schedule of follow-up is described in Table 9.

Table 9: Follow-up for post-orchietomy radiotherapy or chemotherapy – stage I seminoma

Procedure	Year			
	1	2	3	4-5
Physical examination	6 times	4 times	3 times	2/year
Chest X-ray	6 times	4 times	3 times	2/year
Tumour markers	6 times	4 times	3 times	2/year
Abdominal CT scan	Once	Once	If indicated	If indicated
Abdominal ultrasound	Once ^a	Once ^a	Once	If indicated

^a Alternating with abdominal computed tomography scan.

9.5.2 Follow-up after surveillance

It must be recognized that there is a somewhat higher need for salvage chemotherapy if prophylactic radiotherapy is omitted. Alternatively, at least 80% of patients will receive unnecessary radiotherapy if this is given prophylactically to all those with seminoma stage I. There are already prospective, but not randomized, studies of surveillance showing that the actuarial risk of relapse at 5 years ranges between 15% and 20% (17-21). Nevertheless, there is no increased risk of death. The median time to relapse ranges from 12-18 months, but up to 29% of relapses can develop later (1). The sites of relapse are the PA lymph nodes in up to 82% of cases; the pelvic lymph nodes, inguinal nodes and lungs can also be affected (1). Due to the high and often late rate of relapse, close and active follow-up is mandatory for at least 5 years. The major disadvantages of this policy are lack of long-term follow-up data, high costs and patient compliance. The schedule of follow-up is described in Table 10.

Table 10: Follow-up in surveillance policy

Procedure	Year				
	1	2	3	4-5	6-10
Physical examination	Six times	Four times	Three times	Twice/year	Once/year
Tumour markers	Six times	Four times	Three times	Twice/year	Once/year
Chest X-ray	Six times	Four times	Three times	Twice/year	Once/year
Abdominal computed tomography scan	Four times	Four times	Twice	Once/year	If indicated
Abdominal ultrasound	^a	^a	Twice ^b	Once/year ^b	If indicated

^a Not required.

^b Alternating with abdominal computed tomography scan.

9.5.3 Follow-up after adjuvant chemotherapy

One or two courses of carboplatin-based chemotherapy is an effective alternative treatment in stage I seminoma. The relapse rate is less than 2%, but the number of patients treated in a prospective setting is still low and the length of follow-up is also limited in most studies. In general, this treatment is well tolerated, with only mild, acute and intermediate-term toxicity (22,23). As the relapse rate is low, the follow-up schedule may be the same as the one proposed for post-orchietomy radiotherapy (Table 9).

9.6 REFERENCES (Follow-up stage I seminoma)

- Warde P, Jewett MA.**
Surveillance for stage I testicular seminoma. Is it a good option? *Urol Clin North Am* 1998;25:425-433.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9728212&dopt=Abstract
- McCaffrey JA, Bajorin DF, Motzer RJ.**
Risk assessment for metastatic testis cancer. *Urol Clin North Am* 1998;25:389-395.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9728209&dopt=Abstract
- Buchholz TA, Walden TL, Prestidge BR.**
Cost-effectiveness of post-treatment surveillance after radiation therapy for early stage seminoma. *Cancer* 1998; 82:1126-1133. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9506359&dopt=Abstract
- Tana S, Cerrotta A, Gardani G, Palazzi M, Pizzocaro G.**
Post surgical policy in stage I testicular seminoma: cost and benefit of prophylactic irradiation in a long-term experience. *Tumori* 1997;83:918-921. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9526584&dopt=Abstract
- Sharda NN, Kinsella TJ, Ritter MA.**
Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early-stage testicular seminoma. *J Clin Oncol* 1996;14:2933-2939. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8918490&dopt=Abstract
- Sultanem K, Souhami L, Benk V, Bahary JP, Roman T, Shenouda G, Freeman C.**
Para-aortic irradiation only appears to be adequate treatment for patients with stage I seminoma of the testis. *Int J Radiat Oncol Biol Phys* 1998;40:455-459. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9457835&dopt=Abstract

7. **Fossa SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ, Jones WG, Yosef H, Duchesne GM, Owen JR, Grosch EJ, Chetiyawardana AD, Reeds NS, Widmer B, Stenning SP.**
Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. *J Clin Oncol* 1999;17:1146-1154. EBM Ib.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10561173&dopt=Abstract
8. **Kiricuta IC, Sauer J, Bohndorf W.**
Omission of the pelvic irradiation in stage I testicular seminoma: a study of postorchietomy paraaortic radiotherapy. *Int J Radiat Oncol Biol Phys* 1996;35:293-298. EBM Ib.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8635936&dopt=Abstract
9. **Melchior D, Hammer P, Fimmers R, Schuller H, Albers P.**
Long term results and morbidity of paraortic compared with paraortic and iliac adjuvant radiation in clinical stage I seminoma. *Anticancer Res* 2001;21:2989-2993. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11712799&dopt=Abstract
10. **Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Naylor S, Tenning SP.**
A randomized trial of two radiotherapy schedules in the adjuvant treatment of stage I seminoma (MSC TE 18). *E J Cancer* 2001; 37 (1) abstract book : S 157. (Abstract 572). EBM Ib.
11. **Warde P, Gospodarowicz MK, Panzarella T, Catton CN, Sturgeon JF, Moore M, Goodman P, Jewett MA.**
Stage I testicular seminoma: results of adjuvant irradiation and surveillance.
J Clin Oncol 1995;13:2255-2262. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7666083&dopt=Abstract
12. **Livey JE, Taylor B, Mobarek N, Cooper RA, Carrington B, Logue PJ.**
Patterns of relapse following radiotherapy for stage I seminoma of the testis: implications for follow-up. *Clin Oncol (R Coll Radiol)* 2001;13:296-300.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11554630&dopt=Abstract
13. **Fossa SD, Aass N, Kaalhus O.**
Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients. *Int J Radiat Oncol Biol Phys* 1989;16:383-388. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2921142&dopt=Abstract
14. **Baniel J, Foster RS, Einhorn LH, Donohue JP.**
Late relapse of clinical stage I testicular cancer. *J Urol* 1995;154:1370-1372. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7658541&dopt=Abstract
15. **Stein ME, Leviov M, Drumea K, Moshkovitz B, Nativ O, Milstein D, Sabo E, Kuten A.**
Radiation-induced tumors in irradiated stage I testicular seminoma: results of a 25-year follow-up (1968-1993). *J Surg Oncol* 1998;67:38-40. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9457255&dopt=Abstract
16. **Akimoto T, Takahashi I, Takahashi M, Yamakawa M, Hayakawa K, Mitsunashi N, Niibe H.**
Long-term outcome of postorchietomy radiation therapy for stage I and II testicular seminoma. *Anticancer Res* 1997;17:3781-3785. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9427780&dopt=Abstract
17. **Von der Maase H, Specht L, Jacobsen GK, Jakobsen A, Madsen EL, Pedersen M, Rorth M, Schultz H.**
Surveillance following orchidectomy for stage I seminoma of the testis.
Eur J Cancer 1993;14:1931-1934. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8280484&dopt=Abstract
18. **Horwich A, Alsanjari N, A'Hern, Nicholls J, Dearnaley DP, Fisher C.**
Surveillance following orchidectomy for stage I testicular seminoma. *Br J Cancer* 1992;65:775-778. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1586607&dopt=Abstract

19. **Germá Lluch JR, Climent MA, Villavicencio H, Gomez de Segura G, Blanco R, Mercedes A, de Andres L, Sole Balcells FJ.**
Treatment of stage I testicular tumors. Br J Urol 1993;71:473-477. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8499994&dopt=Abstract
20. **Warde P, Gospodarowicz MK, Goodman PJ, Sturgeon JF, Jewett MA, Catton CN, Richmond H, Thomas GM, Duncan W, Munro AJ.**
Results of a policy of surveillance in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 1993;27:11-15. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8365931&dopt=Abstract
21. **Allhoff EP, Liedke S, de Riese W, Stief C, Schneider B.**
Stage I seminoma of the testis: adjuvant radiotherapy or surveillance? Br J Urol 1991;68:190-194. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1715798&dopt=Abstract
22. **Krege S, Kalund G, Otto T, Goepel M, Rubben H.**
Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Eur Urol 1997;31:405-407. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9187898&dopt=Abstract
23. **Dieckmann KP, Krain J, Kuster J, Bruggeboes B.**
Adjuvant carboplatin treatment for seminoma clinical stage I. J Cancer Res Clin Oncol 1996; 122:63-66. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8543595&dopt=Abstract

9.7 Follow-up of stage II and advanced (metastatic) disease

The more advanced the nodal stage of the disease, the higher the likelihood of recurrence (1). In general, the primary tumour bulk governs the outcome for patients with NSGCT (2). In stage II NSGCT, regardless of the treatment policy adopted, excellent survival rates of 97% are reached provided that relapse is identified as soon as possible (3-5).

In advanced metastatic germ cell tumours, the extent of the disease is correlated with the response to therapy and with survival. The combination of cisplatin-based chemotherapy and surgery (aggressive multimodality) achieves cure rates between 65% and 85%, depending on the initial extent of disease (2,6). Complete response rates to chemotherapy are in the order of 50-60% (2); another 20-30% of patients could be rendered disease free with post-chemotherapy surgery (7).

The main reasons for failure of therapy in advanced NSGCT are (2,8,9):

- The presence of bulky disease not responding completely to chemotherapy
- Unresectable residual teratoma after chemotherapy
- Presence or development of chemoresistant non-germ elements, which account for 8.2% of cases

There is a lack of randomized trial results from which to plan evidence-based follow-up, and the different schedules used by various centres have a higher variability and are more individualized than for stage IA.

9.7.1 Clinical and pathological stage II NSGCT

As previously stated in this guidelines low-volume stage II NSGCT can be treated by primary RPLN or primary chemotherapy.

9.7.1.1 Relapse after primary RPLND

Two different situations can occur:

1. About 23-28% of clinical stage II patients will have pathological stage I disease and should be followed up accordingly (see follow-up for NSGCT stage I) (10,11).
2. Between 72% and 77% of clinical stage II patients will be of pathological stage II, having a different relapse rate depending on the type of treatment. Whatever the treatment policy chosen, the majority of relapses occur within the first 2 years and outside the surgical field.

Relapse after primary RPLND followed by two immediate cycles of chemotherapy

The relapse rate for this group is 6% at 4 years (1,6). In non-randomized series, with a mean follow-up ranging from 30-72 months, this treatment policy results in a high overall disease-free survival rate of 98-100% (3,12).

The main disadvantage of adjuvant chemotherapy is that it represents an overtreatment in approximately 50% of patients with stage II disease.

Relapse after primary RPLND followed by surveillance

The average relapse rate in this group is 35% (range 8-49%) at a mean of 4 years (1,13,14). Nevertheless, the relapse rate depends on pathological stage; pathological stage IIa presents a risk of relapse of less than 50%, while pathological stage IIb presents a risk of relapse of at least 50% (1,3,6,15).

Following primary RPLND the retroperitoneal CT scan can be replaced by a less expensive abdominal ultrasound, although a baseline post-RPLND CT scan is recommended (Table 11). When primary RPLND is followed by surveillance (generally in cases of low-volume lymph node involvement or pathological stage IIa), a stricter schedule of follow-up is needed than with adjuvant chemotherapy. A physical examination, tumour marker assessment and chest X-ray are performed more frequently than in the former treatment policy. The follow-up outlined in Table 11 can be used, but the tests have to be performed:

- Monthly during the first year
- Bimonthly during the second year
- Three-monthly during the third year
- Every 4 months during the fourth year
- Twice in the fifth year
- Yearly thereafter

Table 11: Follow-up of NSGCT stage IIa–IIb after RPLND plus chemotherapy or primary chemotherapy

Procedure	Year					
	1	2	3	4	5	Thereafter
Physical examination	Bimonthly	Four times	Twice	Twice	Twice	Once/year
Tumour markers	Bimonthly	Four times	Twice	Twice	Twice	Once/year
Chest X-ray	Bimonthly	Four times	Twice	Twice	Twice	Once/year
Abdominal CTab	Baseline, then as indicated	As indicated	If indicated	If indicated	If indicated	If indicated
Abdominal ultrasound	Twice	Twice	If indicated	If indicated	If indicated	If indicated

CT = computed tomography.

^a After RPLND, a baseline CT scan of the abdomen and pelvis is obtained, and repeated if clinically indicated thereafter.

^b After primary chemotherapy, the retroperitoneum has to be monitored by means of CT scan at least twice during the first 2 years.

9.7.1.2 Relapse after primary chemotherapy

Between 68% and 78% of patients (average 75%) will reach a clinical complete response (5,16,17). The relapse rate is then around 5%, and most relapses occur in the first 8 months after chemotherapy, continuing up to 2 years. Nevertheless, later relapses in the range 2-5% may occur depending on several prognostic factors (e.g. whether the metastasis is: > 3 cm or < 3 cm in size, histology of the primary tumour/teratoid elements). Mature teratomas have been described at 5-8 years of follow-up (3). Generally, the relapse rate at a median follow-up of 5.5 years is approximately 8%. The progression-free survival rate is approximately 92% and the overall survival rate is 97% (5).

Although this treatment policy avoids RPLND in 68-78% of patients, depending on whether the clinical stage is IIa or IIb (5,16,18), it requires extended follow-up. After primary chemotherapy, retroperitoneal CT scans cannot be omitted from the follow-up schedule. The follow-up schedule is basically the same as that for primary RPLND plus adjuvant chemotherapy, although after primary chemotherapy an abdominal and pelvic CT scan has to be performed at least twice during the first 2 years (Table 11).

9.7.2 Clinical stage II seminoma

Relapse rates following radiotherapy for clinical stages IIa and IIb are in the range 5-15%. Most relapses occur within the first 2 years and present with a supraclavicular or mediastinal mass, while relapses in the irradiated field are rare (6). The recommend follow-up schedule is outlined in Table 12.

Table 12: Follow-up of seminoma stage IIa–IIb after radiotherapy

Procedure	Year					
	1	2	3	4	5	> 5
Physical examination	Six times	Four times	Three times	Twice	Twice	Once/year
Tumour markers	Six times	Four times	Three times	Twice	Twice	Once/year
Chest X-ray	Six times	Four times	Three times	Twice	Twice	Once/year
CT abdomen and pelvis ^a	If indicated					
CT chest ^b	If indicated					

CT = computed tomography.

^a Baseline CT of the abdomen/pelvis post-treatment and repeated only if indicated.

^b Only if there is an abnormal chest X-ray or if clinical symptoms indicate.

9.7.3 Clinical stage IIc and III seminoma and non-seminoma

In advanced disease following the IGCCG classification, the overall survival rate is in the order of 92% for patients in the good prognostic category, 80% for those in the intermediate category and 48% for those in the poor prognostic category (19). Stage IIc is generally grouped in the subset of patients with good prognosis (3). After chemotherapy, careful follow-up observation is recommended if there is a decrease of at least 90% in the volume of retroperitoneal masses, provided there was no evidence of teratomatous elements in the primary tumour. Nevertheless, to date there are no reliable CT scan criteria to distinguish tumour or teratoma from necrotic debris in the post-chemotherapy setting; false-negative CT scan rates range from 8-37% (8). In advanced NSGCT, despite statistical correlation with a variety of factors (e.g., degree of shrinkage, size of residual mass, pre-chemotherapy tumour marker levels, teratomatous components in orchiectomy specimen), the risk of a false-negative prediction based on a CT scan is still currently approximately 20% (8). In advanced seminoma, the rate of 'in-site' failure is 3% when the CT scan is normal or shows a residual abnormality less than 3 cm in diameter (20-23). The follow-up schedule for advanced disease (seminoma and non-seminoma) is presented in Table 13.

In advanced disease routine estimation of serum tumor markers (β -hCG and AFP) seems to be the single most important follow-up procedure followed by the physical examination and the clinical history (24-25), some recent studies questioning the value of the routine chest X-ray test (25).

A brain CT has to be performed during follow-up if neurological symptoms are present, because up to 5% of patients with advanced disease present with or develop brain metastases (6). An abdominal CT scan has to be performed at least annually, because of the ominous significance of teratoma, if found in the retroperitoneum.

Table 13: Follow-up of advanced NSGCT and seminoma

Procedure	Year					
	1	2	3	4	5	Thereafter
Physical examination	Monthly	Bimonthly	Four times	Three times	Twice	Once/year
Tumour markers	Monthly	Bimonthly	Four times	Three times	Twice	Once/year
Chest X-ray	Monthly	Bimonthly	Four times	Three times	Twice	Once/year
Abdominal CT ^{ab}	As indicated					
Chest CT ^{bc}	As indicated					
Brain CT ^d	As indicated					

CT = computed tomography.

^a Abdominal CT scan has to be performed at least annually if teratoma is found in retroperitoneum.

^b If the post-chemotherapy evaluation shows any mass > 3 cm, the appropriate CT scan should be repeated 2 and 4 months later to ensure that the mass is continuing to regress.

^c Chest CT is indicated if abnormality is detected on chest X-ray and after pulmonary resection.

^d In patients with headaches, focal neurological findings or any CNS symptom.

9.8 REFERENCES (Follow-up stage II and advanced disease)

1. **Williams SD, Stablein DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP, Paulson DF, Brunner KW, Jacobs EM, Spaulding JT.**
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. *N Engl J Med* 1987;317:1433-1438. EBM Ib.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2446132&dopt=Abstract
2. **Bukowski RM.**
Management of advanced and extragonadal germ-cell tumors. *Urol Clin North Am* 1993;20:153-160.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8381995&dopt=Abstract
3. **Frohlich MW, Small EJ.**
Stage II nonseminomatous testis cancer: the roles of primary and adjuvant chemotherapy. *Urol Clin North Am* 1998;25:451-459.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9728214&dopt=Abstract
4. **Baniel J, Donohue JP.**
Cost and risk benefit considerations in low stage (I and II) nonseminomatous testicular tumors. *AUA Update Series* 1997;7:50-55.
5. **Horwich A, Norman A, Fisher C, Hendry WF, Nicholls J, Dearnaley DP.**
Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. *J Urol* 1994;151:72-77. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8254836&dopt=Abstract
6. **Fair W, Dalbagni G, Machele Donat S, Theodorescu D.**
Evaluation and follow-up of patients with urologic cancer. *AUA Office of Education Publications* 9958 PG, 1999.
7. **Pizzocaro G.**
Non-seminomatous germ-cell tumors (NSGCT) of the testis: diagnosis and management, stage by stage. *European Urology Update Series* 1997;6:139-145.
8. **Sheinfeld J, Bajorin DF, Solomon M.**
Management of postchemotherapy residual masses in advanced germ cell tumors. *Urol Clin North Am* 1997;3:18-23.
9. **Little JS, Foster RS, Ulbright TM, Donohue JP.**
Unusual neoplasms detected in testis cancer patients undergoing postchemotherapy retroperitoneal lymphadenectomy. *J Urol* 1994;152:1144-1149. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8072083&dopt=Abstract
10. **Aas N, Kaasa S, Lund E, Kaalhus O, Heier MS, Fossa SD.**
Long-term somatic side-effects and morbidity in testicular cancer patients. *Br J Cancer* 1990;61:151-155. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2297486&dopt=Abstract
11. **Donohue JP, Thornhill JA, Foster RS, Bihle R, Rowland RG, Einhorn LH.**
The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University Experience (1965 to 1989). *J Urol* 1995;153:85-89. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7966799&dopt=Abstract
12. **Motzer RJ, Sheinfeld J, Mazumdar M, Bajorin DF, Bosl GJ, Herr H, Lyn P, Vlamis V.**
Etoposide and cisplatin adjuvant therapy for patients with pathological stage II germ cell tumors. *J Clin Oncol* 1995;13:2700-2704. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7595727&dopt=Abstract

13. **Rabbani F, Sheinfeld J, Farivar-Mohseni H, Leon A, Rentzepis MJ, Reuter VE, Herr HW, McCaffrey JA, Motzer RJ, Bajorin DF, Bosl GJ.**
Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol 2001;19:2020-2025. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11283135&dopt=Abstract
14. **Hermans BP, Sweeney CJ, Foster RS, Einhorn LE, Donohue JP.**
Risk of systemic metastases in clinical stage nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol 2000;163:1721-1724. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10799168&dopt=Abstract
15. **Hartlapp JH, Weissbach L, Bussar-Maatz R.**
Adjuvant chemotherapy in nonseminomatous testicular tumor stage II. Int J Androl 1987;10:277-284.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2438221&dopt=Abstract
16. **Logothetis CJ, Swanson DA, Dexeus F, Chong C, Ogden S, Ayala AG, von Eschenbach AC, Johnson DE, Samuels ML.**
Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients. J Clin Oncol 1987;5:906-911. EBM IIb.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2438389&dopt=Abstract
17. **Sternberg CN.**
Role of primary chemotherapy in stage I and low volume stage II nonseminomatous germ-cell testis tumors. Urol Clin North Am 1993;20:93-109.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8382000&dopt=Abstract
18. **Foster RS, Donohue JP.**
Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy? Urol Clin North Am 1998;25:479-484.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9728217&dopt=Abstract
19. **International Germ Cell Collaborative Group.**
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603. EBM Ia-IIa-IIb-III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9053482&dopt=Abstract
20. **Peckham MJ, Howick A, Hendry WF.**
Advanced seminoma treatment with cisplatin based combination chemotherapy or carboplatin. Br J Cancer 1985; 52:7-13. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3893507&dopt=Abstract
21. **Fossa SD, Borge L, Aass N, Johannessen NB, Stenwig AE, Kaalhus O.**
The treatment of advanced metastatic seminoma, experience in 55 cases. J Clin Oncol 1987;5:1071-1077. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2439660&dopt=Abstract
22. **Loehrer PJ Sr, Birch R, Williams SD, Greco FA, Einhorn LH.**
Chemotherapy of metastatic seminoma: the SouthEastern Cancer Study Group experience. J Clin Oncol 1987;15:1212-1220. EBM Ib.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2442317&dopt=Abstract
23. **Motzer R, Bosl G, Heelan R, Fair W, Whitmore W, Sogani P, Herr H, Morse M.**
Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 1987;5:1064-1070. EBM III.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3598610&dopt=Abstract

24. Rathmell AJ, Brand IR, Carey BM, Jones WG.

Early detection of relapse after treatment for metastatic germ cell tumour of the testis: an exercise in medical audit. Clin Oncol (R Coll Radiol) 1993;5:34-38. EBM III.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7678749&dopt=Abstract

25. Gietema JA, Meinardi MT, Sleifer DT, Hoekstra HJ, van der Graaf WT.

Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. Ann Oncol, 2002;13:1616-1620. EBM III.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12377651&dopt=Abstract

** These EAU Guidelines on Testicular Cancer are endorsed by all members of the EAU Oncological Urology Group (Chairman: C. Abbou). Members of the Oncological Urology Group are the EAU Working parties on: Bladder Cancer, Renal Cell Cancer, Penile Cancer, Prostate Cancer & Testis Cancer.*

10 ABBREVIATIONS USED IN THE TEXT

This list is not comprehensive for the most common abbreviations.

AFP:	Alpha-fetoprotein
BEP	bleomycin, etoposide & cisplatin
beta-hCG:	beta-human chorionic gonadotrophin
CgA:	Chromogranine A
CT:	Computed tomography
EP:	Etoposide and Cisplatin
EORTC:	European Organization for Research and Treatment of Cancer
FDG-PET:	Fluorodeoxyglucose-positron-emission tomography
IGCCCG:	International Germ Cell Cancer Collaborative Group
LH:	luteinizing hormone
LDH:	Lactate Dehydrogenase
MMSK:	Memorial Sloan Kettering
MRC:	Medical Research Council
MRI:	Magnetic resonance Imaging
NSE:	Neuro-specific Enolase
NSGCT:	Non-seminomatous germ cell tumour
PEB:	Cisplatin, Etoposide and Bleomycin
PEI:	Cisplatin, Etoposide, Ifosfamide
PET:	positron emission tomography
PVI:	Cisplatin, Vinblastine, Ifosfamide
PLAP:	Placental alkaline Phosphatase
PVB:	Cisplatin, Vinblastine and Bleomycin
RPLND:	Retroperitoneal lymph node dissection
Tin:	Intratubular germ cell neoplasia
TNM:	Tumour Node Metastasis
UICC:	International Union Against Cancer
VAB:	Vinblastine, Adriamycin and Bleomycin
VelP:	Velvan, Ifosfamide and Cisplatin